The Texas Medical Center Library

DigitalCommons@TMC
The University of Texas MD Anderson Cancer
Center UTHealth Graduate School of
Biomedical Sciences Dissertations and Theses
(Open Access)

The University of Texas MD Anderson Cancer
Center UTHealth Graduate School of
Biomedical Sciences

12-2012

PROSTATE CANCER STEM CELLS: DRUG TOLERANCE,
EXPERIMENTAL RECONSTITUTION AND CASTRATION
RESISTANCE
Xin Chen

Follow this and additional works at: https://digitalcommons.library.tmc.edu/utgsbs_dissertations
Part of the Life Sciences Commons, and the Medicine and Health Sciences Commons

Recommended Citation
Chen, Xin, "PROSTATE CANCER STEM CELLS: DRUG TOLERANCE, EXPERIMENTAL RECONSTITUTION
AND CASTRATION RESISTANCE" (2012). The University of Texas MD Anderson Cancer Center UTHealth
Graduate School of Biomedical Sciences Dissertations and Theses (Open Access). 302.
https://digitalcommons.library.tmc.edu/utgsbs_dissertations/302

This Dissertation (PhD) is brought to you for free and
open access by the The University of Texas MD Anderson
Cancer Center UTHealth Graduate School of Biomedical
Sciences at DigitalCommons@TMC. It has been
accepted for inclusion in The University of Texas MD
Anderson Cancer Center UTHealth Graduate School of
Biomedical Sciences Dissertations and Theses (Open
Access) by an authorized administrator of
DigitalCommons@TMC. For more information, please
contact digitalcommons@library.tmc.edu.

PROSTATE CANCER STEM CELLS: DRUG TOLERANCE, EXPERIMENTAL
RECONSTITUTION AND CASTRATION RESISTANCE

by
Xin Chen, M.S.

APPROVED:
______________________________
Supervisory Professor: Dean G. Tang, M.D., Ph.D.
______________________________
Ellen R. Richie, Ph.D.
______________________________
Donna F. Kusewitt, D.V.M, Ph.D.
______________________________
Feng Wang-Johanning, M.D., Ph.D.
______________________________
Taiping Chen, Ph.D.

APPROVED:
___________________________
Dean, The University of Texas
Graduate School of Biomedical Sciences at Houston

PROSTATE CANCER STEM CELLS: DRUG TOLERANCE, EXPERIMENTAL
RECONSTITUTION AND CASTRATION RESISTANCE

A
DISSERTATION
Presented to the Faculty of
The University of Texas
Health Science Center at Houston
and
The University of Texas
M. D. Anderson Cancer Center
Graduate School of Biomedical Sciences
in Partial Fulfillment
of the Requirements
for the Degree of
DOCTOR OF PHILOSOPHY
by
Xin Chen, M.S.
Houston, Texas
December, 2012

DEDICATION
To my dearest parents, Dr. Weimin Chen and Ms. Guimei Peng,
who made all this possible,
and for their eternal love and endless support;
To my beloved wife, Ms. Qiuhui Li,
for her patience, encouragement and company,
and for her incomparable love

iii	
  
	
  

ACKNOWLEDGMENTS

I have been in Science Park for more than 7 years, during which I have experienced
both great joys and great disappointments. I vividly remember the excitement that filled my
heart when my first paper was published. But then there was the crushing heartbreak of
losing nearly two years worth of samples due to the 2011 Bastrop Wildfire. Given the good
and bad I have experienced during my time here, I still consider myself a lucky person. That
luck has been largely ascribed to the people I have been honored to know and work with,
and I would like to take this opportunity to express my gratitude for their contributions.
First and foremost, I would like to thank my advisor, Dr. Dean G. Tang. I have
known Dean since I was a child, for he is my father’s best friend. He was a great support to
me before I even came to the US. However, when I did arrive in the US, I was then lucky
enough to enter GSBS and join his lab, starting as a Master’s student. Dean is a great
scientist and a wonderful individual as well. During the past 7 years, his dedication,
intelligence, persistence, passion, enthusiasm, vigorousness and remarkable memory have
impressed me and significantly influenced me to purse my dream. His guidance, patience,
support and strictness have made it possible for me to take this journey and reach this point.
There are no words to adequately express my appreciation and gratitude, but I would like to
say, sincerely, ‘Thank you very much, Dean”.
Moreover, I would like to thank my advisory, candidacy and supervisory committee
members, Dr. Susan Fischer, Dr. Ellen Richie, Dr. Donna Kusewitt, Dr. Feng WangJohanning, Dr. Mark Bedford, Dr. Taiping Chen, Dr. David Mitchell, Dr. Gary Johanning,

iv	
  
	
  

and Dr. Robin Fuchs-Young. They are always supportive and their insights, expertise and
wisdom have helped me a great deal to accomplish this work.
Furthermore, I would like to thank all past and present Tang Lab members for their
years of friendship: Ms. Tammy Davis, Dr. Collene Jeter, Mr. Bigang Liu, Dr. Can Liu, Dr.
Kiera Rycaj, Dr. Mahipal Suraneni, Dr. Dingxiao Zhang, Mr. Xin Liu, Ms. Qu Deng, Mr.
John Moore, Dr. Mark Badeaux, Dr. Hangwen Li, Dr. Jichao Qin, Dr. Hong Yan, Ms. Shuai
Gong, Ms. Min Jin, and Ms. Yang Shi. A special thank-you goes to Ms. Tammy Davis and
Mr. Bigang Liu for being true friends, and Dr. Kiera Rycaj for proof-reading my draft
dissertation.
I am also grateful to all my other friends and colleagues at Science Park for their
help, encouragement, and support. Especially, I am thankful to Dr. Jianjun Shen, Ms. Pam
Whitney, Mr. Kevin Lin, and Ms. Rebecca Deen for their unselfish assistance in my
research. In addition, I would like to thank a few wonderful individuals at GSBS who are
always generous with their time and expertise, helping me to clear the roadblocks I came
across during this journey: Dr. Vicki Knutson, Ms. Bunny Perez, and Ms. Becky Brooks.
Additionally, I would like to express my sincere gratitude to a few people for their
moral support and constant encouragement, without which this work would have been much
more difficult: Mr. Alex Zacharek, Ms. Grace Zacharek, and Dr. Kim Cardenas.
Last but not the least, I am eternally grateful for the love, patience and support from
my parents and my wife.
	
  

v	
  	
  

PROSTATE CANCER STEM CELLS: DRUG TOLERANCE, EXPERIMENTAL
RECONSTITUTION AND CASTRATION RESISTANCE
Publication No.________
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Supervisory Professor: Dean G. Tang, M.D., Ph.D.
Prostate cancer (PCa) is one of the leading malignancies affecting men in the
Western world. Although tremendous effort has been made towards understanding PCa
development and developing clinical treatments in the past decades, the exact mechanisms
of PCa are still not clearly understood. Emerging evidence has postulated that a population
of stem cell-like cells inside a tumor, termed ‘cancer stem cells (CSCs)’, may be the cells
responsible for tumor initiation, progression, recurrence, metastasis and therapy resistance.
Like CSC studies in other cancer types, it has been reported that PCa also contains CSCs.
However, there remain several unresolved questions that need to be clarified. First, the
relationship between prostate CSCs (PCSCs) and therapy resistance (chemo- and radio-) is
not known. Herein, we have found that not all CSCs are drug-tolerant, and not all drugtolerant cells are CSCs. Second, whether primary human PCa (HPCa) actually contain
PCSCs remains unclear, due to the well-known fact that we have yet to establish a reliable
assay system that can reproducibly and faithfully reconstitute tumor regeneration from
single HPCa cells. Herein, after utilizing more than 114 HPCa samples we have provided
evidence that immortalized bone marrow-derived stromal cells (Hs5) can help dissociated
HPCa cells generate undifferentiated tumors in immunodeficient NOD/SCID-IL2Rγ-/- mice,
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and the undifferentiated PCa cells seem to have a survival advantage to generate tumors.
Third, the evolution of PCa from androgen dependent to the lethally castration resistant
(CRPC) stage remains enigmatic, and the cells responsible for CRPC development have not
been identified. Herein, we have found a putative cell population, ALDH+CD44+α2β1+ PCa
cells that may represent a cell-of-origin for CRPC. Taken together, our work has improved
our understanding of PCSC properties, possibly highlighting a potential therapeutic target
for CRPC.
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Chapter 1

Introduction
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Prostate cancer (PCa) is one of the most common malignancies, and the second
leading cause for cancer-related mortality following lung cancer in American males (1).
According to the Cancer Statistics 2012, it was estimated that there will be ~241,740 new
cases and ~28,170 related deaths in the USA this year (1). Although much progress has been
made in the past decades, the exact mechanisms underlying PCa development remain
unclear (2). Emerging evidence has shown that many human malignancies, including PCa,
contain a subset of stem cell-like cancer cells, termed ‘cancer stem cells (CSCs)’, which are
proposed to be responsible to drive tumor formation and progression, mediate therapy
resistance and recurrence, and facilitate metastasis (3-8). The CSC model has provided new
insights into the mechanistic studies of human cancers, which could potentially lead to drug
development and clinical treatments.

1.1. Anatomy of human and mouse prostate
The prostate is a sex hormone regulated organ, which is located at the base of
bladder surrounds the urethra, and contributes to semen production. Based on the seminal
work from McNeal, human prostate glands are classified into three zonal structures, i.e.,
peripheral, central, and transition zones (9-11), and it is widely believed that most human
PCa arise in the peripheral zone, due to the fact that it makes up ~ 70% volume of the
prostate gland (Figure 1-1). In contrast, a mouse prostate is composed of four lobes, i.e.,
dorsal (DP), ventral (VP), lateral (LP) and anterior (AP) lobes (Figure 1-1). It has been
suggested that the mouse dorsolateral prostate and the human peripheral zone are
functionally identical, based on gene profiling (12).
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Figure 1-1. Schematic illustration of the anatomy of the human and mouse prostate.
Taken from (13) with permission from Cold Spring Harbor Laboratory (CSHL) Press.
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1.2. Histology of normal prostate
Histologically, prostate glands (human and mouse) are composed of three different
epithelial cell types: basal, luminal and neuroendocrine cells (2, 14, 15). Basal cells reside in
the basal layer that sits above the basement membrane, and these cells express cytokeratin 5
(CK5), CK14, p63 (16), CD44 (17), CD133, Bcl-2, telomerase, GST-π, and low or
undetectable levels of androgen receptor (AR) protein. In contrast, luminal cells constitute
the luminal layer that situates above the basal layer, generate secretory proteins into the
lumen, and express prostate-specific antigen (PSA), CK8, CK18, CK19, prostatic acid
phosphatase (PAP), 15-lipoxygenase-2 (15-LOX2) (18), CD57 (17), and high levels of AR.
Neuroendocrine cells are localized throughout the basal layer, and express synaptophaysin
and chromogranin A. These cells are rare and their functions are not clearly understood (2,
14, 15).

1.3. Stem cells: definition and identification
In general, normal stem cells (SCs) are defined as cells that are endowed with selfrenewal abilities and differentiation capacities (6, 7, 19). SCs possess several fundamental
characteristics. First, they are generally rare (6). Second, they exist in a specific
microenvironment, termed ‘niche’, where they are maintained in an undifferentiated state
and self-renew if needed (19). Third, recent evidence suggests that adult SCs can be either
quiescent or proliferating (20), whereas most primitive SCs are generally quiescent in the
niche. However, SCs possess high proliferative potential, which can be manifested in
response to stimulation (e.g., injury). Fourth, SCs maintain themselves via self-renewal,
which can be achieved through either asymmetric cell division (ACD), or symmetric cell
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division (SCD). In SCD, a SC replenish itself by generating two identical daughter cells,
while in ACD, a SC can give rise to two distinct daughter cells (an identical SC, and a
committed progenitor cell) (Figure 1-2). The committed progenitor cells generated by SCs
will eventually differentiate into mature cells composing a specific tissue, a process called
differentiation (Figure 1-2).
SCs are typically functionally characterized by tissue reconstitution assays or lineage
tracing (7, 21). In a tissue reconstitution assay, a candidate SC population is isolated by cell
surface marker(s) via florescence-activated cell sorting (FACS), and tested for SC properties
in xeno-, syngeneic, or allogeneic transplantation, to determine if these cells have the ability
to regenerate the tissue from which they are derived. However, the main limitation of this
process is the uncertainty of whether it represents the natural process of regeneration in the
target tissue. Alternatively, the lineage-tracing strategy is designed to circumvent such
confusions, by utilizing a reporter system of ‘stem cell-specific’ inducible Cre mice to
characterize SC properties in their orthotopic sites. However, it is frequently unclear how
relevant the data is to human samples and it is not known how specific Cre recombination is
within the cells (or tissue) of interest.

5	
  	
  

Figure 1-2. Self-renewal and differentiation of stem cells. The stem cell self-renewal is
indicated by curved arrows. Only a uni-potent progenitor cell is depicted. Take from (7)
with permission from Nature Publishing Group.
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Additionally, SCs can be enriched by other ways. For example, a label-retaining
strategy (i.e., BrdU) is commonly used, based on the observations that SCs are quiescent
(22). These label-retaining cells (or LRCs) can then be sorted out by FACS to further
characterize their SCs properties in vivo and in vitro with combined strategies. Furthermore,
SCs can be purified via functional methods, including side population (SP), or the
ALDEFLUOR assay, based on the fact that SCs highly express detoxification molecules,
e.g., ABC transporter ABCG2 in SP, and aldehyde dehydrogenase 1 A1 (ALDH1A1) in the
ALDEFLUOR analysis (23-26). Moreover, in vitro characterization of SC properties
involves two-dimensional clonal cultures and three-dimensional serial sphere-formation
assays, to mainly examine proliferative/clonal potentials and self-renewal abilities,
respectively, of a candidate cell (or a cell population) (27). In reality, none of the abovementioned methods can demonstrate on their own that the candidate cell population is truly
enriched in SCs, and several methods often need to be combined.

1.4. Normal prostate stem cells (PSCs): identification and characterization
Previous studies have shown that the adult rodent prostate regresses after castration,
but will return to normal size after androgen restoration. Such regression-restoration events
can be repeated for multiple cycles (28, 29), which strongly suggests the presence of PSCs.
Using the BrdU label-retaining strategy, BrdU+ basal and luminal cells in the proximal
region of the prostate have been identified after 39 weeks (16 cycles) of prostate regressionrestoration. Importantly, such slow-cycling cells have a high proliferative potential and can
regenerate glandular structures in vitro that are positive for both CK8 and CK14 (30). In the
past decade, many studies in animal models have reported the presence of putative PSCs in
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both basal and luminal layers, but the interpretations of these data are highly dependent on
the methodology utilized.

1.4.1. Normal PSCs in mice: basal origin
During prostate regression, ~90% of luminal cells and a small subset of basal cells
undergo apoptosis after androgen deprivation, indicating that the castration-resistant PSCs
are likely to be localized in the basal cell layer. Indeed, most recent evidence supports the
hypothesis that basal cells are enriched in PSCs, many of which have been evinced using the
aforementioned tissue reconstitution assay (31). For example, the Sca-1+ basal cells isolated
from the proximal prostatic glands have been shown to be slow cycling and highly capable
of regenerating prostate-like tissues in the renal grafts compared to the corresponding Sca-1cells (32, 33). In addition, most Sca-1+ cells (~60%) are also positive for α6 integrin and
anti-apoptotic molecules Bcl-2 (32). Later studies have shown that Lin-Sca-1+CD49+ (LSC)
prostate cells reside in the basal layer of the proximal region, and are highly enriched for
colony- and sphere-forming cells in vitro and tissue-regenerative cells in vivo (34). Similarly,
the same group has reported that Trop2hi LSC mouse prostate cells, localized in the basal
layer, are further enriched for PSCs using the same experimental strategies (35). Recently,
CD117 (c-kit) expression has been shown to be mainly localized in the proximal region of
mouse prostate glands and is enhanced after castration, suggesting that CD117 is likely a
new

marker

to

enrich

mouse

PSCs

(36).

Interestingly,

a

single

Lin-Sca-

1+CD133+CD44+CD117+ murine prostatic cell is able to reconstitute a prostate in the renal
grafts (~10%), and the regenerated prostate glands contain cells positive for basal-, luminaland neuroendocrine cell-markers (36). In addition, this report has also shown that CD117+

8	
  	
  

cells are preferentially enriched in the basal-cell layer in mouse prostate epithelium (36).
Taken together, these results suggest that some mouse PSCs with regenerative capacity,
identified via the FACS-based tissue reconstitution assays, reside in the basal-cell layer.

1.4.2. Normal PSCs in mice: luminal origin
The possibility that luminal prostatic cells harbor PSCs originated from the early
observations that grafting of urogenital sinus (UGS) from p63-/- mouse embryos can lead to
prostatic tissues under the kidney capsule, which contain luminal and neuroendocrine cells
but lack basal cells (37). In addition, such p63-/- prostate grafts can undergo several cycles of
androgen deprivation and restoration (37). Recently, using a genetic lineage tracing strategy,
a small population of luminal Nkx3.1 - expressing cells, termed ‘CARNs’, have been
reported in castrated mouse prostates, and these cells possess long-term self-renewal
potentials in vivo (38). CARNs are capable of reconstituting a prostate at the single-cell level
when used in tissue reconstitution assays (38). Dr. Li Xin’s group used lineage tracing
approach in double transgenic mouse model (K14-CreERTg/Tg; mTmGTg/Tg) to show that, in
adult mouse prostate, the GFP-labeled prostate basal cells can only give rise to basal cells
positive for CK5 after prostate gland regression-restoration experiments (39). When they
employed a similar strategy in another double transgenic mouse model (K8-CreERT2Tg/Tg;
mTmGTg/Tg), they observed that the GFP-labeled prostate luminal cells can only give rise to
luminal cells positive for CK8 after the regression-restoration experiments (39). These
results seem to suggest that in adult mouse prostates, there exist lineage-restricted progenitor
cells that can regenerate cells in the same lineage. Interestingly, the same study (39)
provided evidence that prostate luminal cells are more sensitive to malignant transformation
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in a PTEN-null model whereas prostate basal cells, seemingly, need to first differentiate into
transformation-competent luminal cells before they can be oncogenically transformed by
PTEN loss (39). These data suggest that although both prostate basal and luminal layers
harbor cells that can self sustain in vivo, the prostate luminal cells are more susceptible to
direct oncogenic transformation than basal cells (39). Another group recently has combined
the lineage tracing and prostate regression-restoration assays in their double transgenic
mouse model (PSA-CreERT2/R26-lacZ and PSA-CreERT2/Rosa26R mT/mG) and reported
that the preexisting luminal cells harbor castration-resistant cells, which can generate new
luminal cells in vivo (40). Collectively, these results all suggest that luminal cells may also
contain a subset of PSCs or progenitor cells.
The relationship between each reported PSC population whether basal or luminal is
presently unclear.

1.4.3. Normal PSCs in human
The studies of PSCs in human cells are not feasible due to technical and ethical
issues that will arise if the lineage-tracing strategy is applied. Therefore, the possible
presence of putative PSCs in the human prostate gland have to be inferred from several
pieces of evidence, but mostly from the reports using FACS-based in vivo and in vitro
assays (21). The results from these assays generally suggest that human PSCs are of basal
origin. For instance, ~1% of basal cells from benign human prostate tissues are found to
express high levels of α2β1-integrin, and possess SC properties, based on the observations
that they have more clonogenic and prostate duct-regenerative capacities than other cell
populations (41). In addition, it was later reported that putative human PSCs may be
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enriched in ~1% of human prostate basal cells positive for CD133 and restricted to α2β1integrinhi/+ cell populations, which possess higher proliferative and prostate ductregenerative capacities than the isogenic CD133- cells (42). Similarly, human PSCs can also
be enriched in ~1% of ABCG2 +(BCRP+) cells, which are located in the basal-cell layer
(43). In support, small subsets of human prostate cells are able to form prostaspheres that
display a basal phenotype, i.e., CD44+CD49f+CK5+p63+Trop2+CK8-AR-PSA-, and these
sphere-forming cells can generate prostate-like ducts in renal grafts using the tissue
reconstitution assay (44). However, whether human prostate luminal cells also contain PSCs
is not clear and this possibility cannot be completely excluded.

1.5. Natural history of PCa development
PCa takes time to develop, from normal prostate, to prostatic intraepithelial neoplasia
(PIN), then to early and late stage carcinoma, and finally to metastatic and castration
resistant disease (2). Early-stage PCa patients are commonly treated by radical
prostatectomy with good prognosis, whereas late-stage PCa patients are mainly treated by
androgen-deprivation therapy (ADT) with the majority of patients eventually developing an
incurable and lethal stage termed ‘castration resistant prostate cancer (CRPC)’ (or androgen
independent prostate cancer/AIPC) (45, 46). CRPC has a high propensity to metastasize to
bone, lung, liver and other sites, which creates a barrier for effective clinical treatments
(Figure 1-3).
Histopathologically, the majority (>95%) of PCa are adenocarcinoma, manifested by
the expansion of luminal-like cells expressing high levels of luminal markers, such as AR,
CK18, PSA, and the rarity of basal-like cells expressing low levels of basal markers, such as
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CK5, CK14 and p63. At the molecular level, as shown in Figure 1-3, many key regulators
become dysregulated as PCa develops, such as down-regulation of NKX3.1, up-regulation of
MYC, inactivation of PTEN and TP53, and overexpression of EZH2 and ERK/MAPK, etc
(2). In addition, at the genomic level, the oncogenic gene fusions of TMPRESS2 and ERG
are the most frequent genomic rearrangement in PCa (>50%) (47, 48). However, our
understanding of the etiology for PCa is still superficial, and a great deal of work is still
needed.
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Figure 1-3. Progression pathway for human prostate cancer. Stages of progression are
shown, together with molecular processes and genes/pathways that are likely to be
significant at each stage. Taken from (2) with permission from Cold Spring Harbor
Laboratory (CSHL) Press.
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1.6. CSCs: definition, identification and characterization
Cellular heterogeneity exists in both normal and cancerous tissues. Tumor cell
heterogeneity can be explained by two models: the clonal evolution (stochastic) model and
the cancer stem cell (hierarchical) model (3-8, 21, 49-51). The well-established clonal
evolution model has long been established (52), in which genetic mutations (52) and
epigenetic alterations (53) in the tumor bestow a selective growth advantage, leading to a
dominant clone. In this model, most tumor cells are believed to possess similar
tumorigenicity after clonal selection. In contrast, emerging evidence has shown that in
hematopoietic malignancies and solid tumors, there exists a subset of stem cell-like cancer
cells, namely ‘CSCs’, which stands at the apex of a hierarchy of cancer cells, and are cells
responsible for sustaining tumor development (Figure 1-4). By comparison, non-CSCs or
CSC progeny have much more limited tumorigenicity. Recent evidence suggests that these
two models may not necessarily be mutually exclusive (4, 5, 8, 50).
The CSC model was proposed decades ago. It was reported in 1937 that a single
murine leukemic cell possessed the ability to regenerate tumors in a mouse, providing
evidence for the existence of leukemia-initiating cells (54). In the 1960s and 1970s, several
pieces of evidence from different tumor systems demonstrated the presence of stem-like
cancer cells, which are highly tumorigenic in vivo and could give rise to the bulk of nontumorigenic cells (55-59). Nevertheless, the first definitive evidence for true CSCs came
from John Dick’s lab in the 1990s. They showed that small subsets of leukemic cells from
most of their human AML samples share the same phenotypic markers (CD34+CD38- ) as
normal hematopoietic stem cells, and these CD34+CD38- stem cell-like leukemic cells have
the capacity to serially reinitiate AML in immunodeficient mice (i.e., NOD/SCID) (60, 61).
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In 2003, a report showed that CD44+CD24-/lo human breast cancer cells could
regenerate serially transplantable tumors with as few as 100 cells whereas cells from other
populations were much less tumorigenic, providing the first evidence that CSCs exist in
solid tumors (62). From then on, the CSC model has been widely studied in a variety of
human tumors, including leukemia (63-66), cancers of breast (67-69), brain (70-73),
colon(74-77) , prostate (15, 43, 78-105), lung (106-108), liver (109-111), pancreas (112,
113), kidney (114, 115), bladder (116, 117), ovary (118, 119), head and neck (120), and
melanoma (121-123).
How should a CSC be defined? In theory, a CSC is the cell in a tumor that has the
potential to self-renew and gives rise to all other types of cancer cells. Experimentally, the
CSC hypothesis will be examined in functional studies, in which a population of cancer cells
will be defined as stem-like cancer cells, or ‘CSCs’, by their virtue of reconstituting serially
transplantable tumors that histopathologically resemble, at least partially, the parental tumor.
Therefore, the ‘gold’ standard to test CSC properties of certain cells is to examine their
capacity to reinitiate tumor development and self renew in immunodeficient mice (3)
(Figure 1-5). The reported CSC populations are mainly identified via the approaches similar
to those used to enrich for normal SCs, including FACS-based cell surface markers (60-62)
and functional assays (68, 86), followed by functional validation via injection of such CSCenriched cells into immunodeficient mice at various cell numbers (i.e., limiting dilution
assay/LDA), or plating the sorted cells in vitro to test their serial sphere formation
capacities. The majority of aforementioned studies of CSCs utilized this FACS-based cell
surface marker approach. In addition, recent studies in animal models have provided solid
evidence that CSCs can be tracked using a lineage-tracing strategy in their natural
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microenvironment, i.e., glioma, epidermal squamous cell carcinoma, and intestinal adenoma
(124-126). For example, it has been shown that a subpopulation of glioma tumor cells can be
labeled by a nestin-ΔTK-GFP transgene in the subventricular zone of the brain, where the
adult neural stem cells are localized. After administration of the drug temozolomide (TMZ),
the quiescent GFP+ glioma cells can self-renew and generate GFP- glioma cells, which
comprise the majority of the tumor, suggesting that these quiescent GFP+ glioma cells are
the cells responsible for sustaining long-term glioma growth, are resistant to the drug
treatment, and contain CSCs properties (126). Collectively, current evidence has implied the
existence of CSCs in some, if not all, human and mouse tumors.
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Figure 1-4. Schemata of the clonal evolution and cancer stem cell models. (A) The
clonal evolution model is a nonhierarchical model where mutations arising in tumor cells
confer a selective growth advantage. Depicted here is a cell (red) that has acquired a series
of mutations and produced a dominant clone. Tumor cells (red and orange) arising from this
clone have similar tumorigenic capacity. Other derivatives (grey) may lack tumorigenicity
due to stochastic events. Tumor heterogeneity results from the diversity of cells present
within the tumor. (B) The cancer stem cell model is predicated on a hierarchical
organization of cells, where a small subset of cells has the ability to sustain tumorigenesis
and generate heterogeneity through differentiation. In the example shown, a mutation(s) in a
progenitor cell (depicted as the brown cell) has endowed the tumor cell with stem cell-like
properties. These cells have self-renewing capability and give rise to a range of tumor cells
(depicted as gray and green cells), thereby accounting for tumor heterogeneity. Taken from
(8) with permission from Elsevier.
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However, there is some confusion and misunderstanding about CSCs. First, the
frequency of CSCs is variable and highly dependent on the system studied. For example, a
small subset of melanoma cells (1 in 106) expressing ABCB5 has been shown to have longterm tumor-initiating properties, self-renewal ability in vivo and the ability to differentiate
into ABCB5- bulk cells (121). However, a later study showed that as high as 1 in 4
melanoma cells were CSCs if more immunodeficient mice were utilized (122), suggesting
that the relative abundance of putative CSCs may vary with different strains of
immunodeficient mice, experimental methodologies, and primary samples utilized. Second,
there may be no universal CSC markers for all tumors. It has been reported that CSCs can be
enriched by phenotypic cell surface markers and functional assays, such as CD44 (85),
SSEA-1 (127), ALDH (68), etc. For instance, CD133 has been used to enrich for CSCs in
brain tumors (70). However, in some reports, CD133+ colon cancer cells seem to be equally
tumorigenic to CD133- colon cancer cells (77), indicating that this marker may not discern
CSCs in all types of cancer. Third, CSCs may not necessarily originate from normal stem
cells. It has been postulated that CSCs are derived from their corresponding normal
counterpart, in that CSCs are commonly purified by the markers used for enriching normal
SCs (60, 61). However, recent evidence has shown that CSCs can also originate from
progenitors or differentiated cells. For instance, a study of transformation targets in human
basal-like breast cancer has provided strong evidence that luminal progenitors
(CD49f+EpCAM+) rather than basal stem/progenitor (CD49fhiEpCAM-) are likely the targets
for malignant transformation (128). Similarly, it has been shown that restricted progenitors
in medulloblastoma, the most malignant brain tumor in children, can be malignant targets
via activation of the Sonic hedgehog (Shh) pathway (129). Fourth, CSCs are heterogeneous.
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For example, putative prostate cancer stem cells (PCSCs) can be phenotypically enriched in
different populations, such as CD44+ (85), ALDH1A1+ (91), TRA-1-60+CD151+CD166+
(94), PSA- (98), etc, via distinct methodologies. In most cases, it remains generally unclear
which CSC population represents the most primitive CSCs. Also, the interrelationship
among all CSC-enriched populations is largely unknown. Fifth, CSCs may not necessarily
be all resistant to chemo- and radio- therapy, which I will discuss further in Chapter 2.
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Figure 1-5. Xenograft assays to measure human CSCs. Cancer stem cells (CSCs) are
most rigorously and specifically defined by their demonstrated ability to produce a
progressively growing tumour consisting of cells that resemble those in the original tumour.
For this reason, CSCs are also frequently referred to operationally as tumour-initiating cells.
Limiting-dilution transplants or other clonal tracking strategies are typically used to
determine the frequency of CSCs in the initial tumour-derived cell suspension. Ideally, the
tumours that form in primary hosts are again tested for their content of cells with CSC
activity (demonstrable in injected secondary hosts) to formally confirm that the initial CSCs
had self-replicating ability. These principles apply both to measurements of the CSC
frequency and the total CSC content, either in the bulk population or in isolated
subpopulations of dissociated tumour cells. The most sensitive assays are those in which
there is no immunological difference between the host and the tumour. When this is not
possible (such as for human tumours), xenografts into highly immunodeficient mice are
used. Taken from (50) with permission from Nature Publishing Group.
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1.7. Studies of human PCSCs
Like CSCs reported in other cancer types, PCSCs have been identified mainly based
on studies via FACS-based cell surface markers and functional assays followed by LDA in
xenotransplatation models or in vitro sphere formation assays. Using cell surface markers,
we revealed that CD44+ PCa cells in the xenograft tumors (e.g., Du145, LAPC9 and
LAPC4) are more clonal, clonogenic, tumorigenic and metastatic than the corresponding
CD44- PCa cells (85). More importantly, CD44+ PCa cells are quiescent, express SC-related
molecules (e.g., Oct-3/4, Bmi, β-catenin, and SMO), and can give rise to CD44- PCa cells.
These results suggest that CD44+ PCa cells are enriched in tumorigenic and metastatic
stem/progenitor cells (85). Due to the fact that CSCs are heterogeneous, we reported in
subsequent studies that CD44+α2β1+ combinatorial markers can further enrich for PCSCs in
the LAPC9 model (87). Similar work has been shown in other PCa cell lines and xenograft
models (84, 88, 94, 102, 130). The identification of PCSC in patient samples is
extraordinarily challenging, due to the well-known fact that it is extremely difficult to reinitiate PCa development in immunodeficient mice using single primary HPCa cells (131),
which I will discuss in Chapter 3. Notably, a report has shown that a small subset of primary
HPCa cells expressing the phenotypic markers CD44+α2β1hiCD133+, are highly clonogenic
and proliferative, suggesting the presence of stem-like cancer cells in the patient samples
(78). However, whether these cells harbor tumorigenic and metastatic CSCs is still not clear
as in vivo tumor experiments were not done in this study (78). Taken together, the markerdependent strategy has allowed us to enrich putative PCSCs in PCa cell lines, xenograft
models, and primary and metastatic patient samples.
PCSCs can also be enriched via marker-independent methods. For instance, it has
been shown that ALDH-positive PCa cells are more tumorigenic and metastatic than the
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ALDH-negative PCa cells (91, 93). Also, we have showed that LAPC9 SP cells are much
more tumorigenic (>100-fold) than non-SP cells (86). Furthermore, we have revealed that
the holoclones in PC3 cell cultures harbor stem cell-like PCa cells, compared to the isogenic
meroclones and paraclones, manifested by their enhanced clonogenicity and tumorigenicity
(82). Additionally, a recent study in primary HPCa samples has showed that in vitro serially
passaged prostaspheres contained self-renewal cells expressing high levels of SC makers
(i.e., CD49b+/CD49f+/CD44+/ΔNp63+/Nestin+/CD133+) (90), suggesting that prostaspheres
are likely to be enriched in PCSCs. Most recently, we have provided convincing evidence
that the (PSA-/lo) undifferentiated PCa cell population is enriched in PCSCs via a lentiviral
reporter system from PCa cell lines, xenograft tumors as well as primary untreated patient
samples (98). The PSA-/lo cells are significantly more clonal, clonogenic, quiescent,
tumorigenic, stress-resistant and castration resistant than the isogenic differentiated bulk
PSA+ cells. Furthermore, time-lapse videomicroscopy studies demonstrate that a portion of
PSA-/lo PCa cells can undergo ACD to generate PSA+ cells, a cardinal feature for SCs (132).
Moreover, PSA-/lo cells sustain long-term tumor propagation and can generate serially
transplantable tumors that histologicially resemble their parental tumors. Collectively, these
data unequivocally demonstrate the presence of the long-term PCSCs in the PSA-/lo PCa cell
population, and highlight the importance of PSA-/lo cells as novel therapeutic targets.
What are the possible mechanisms to regulate PCSCs in human cancer? It has been
shown that CD133+/CD44+ PCa cells (DU145 and PC3) are enriched in stem cell-like cells
and can be propagated in sphere-forming conditions, in which PTEN/PI3K/AKT signaling is
activated. Administration of the dual PI3K/mTOR inhibitor NVP-BEZ235 significantly
inhibits tumor growth of CD133+/CD44+ PCa cells (89), raising a possibility that the
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PTEN/PI3K/AKT pathway may be critical for PCSC properties. Our lab has recently shown
that NANOG, a transcription factor essential for ESCs pluripotency and self-renewal (133),
may play a role in regulating CSC properties as evidenced via loss and gain of function
experiments (80, 81). Most recently, a subset of docetaxel-resistant PCa cells have been
shown to harbor tumor initiating cells and overexpress Notch and Hedgehog signaling
pathways. Specific targeting of these two pathways significantly inhibits tumor regrowth of
these drug-resistant PCa cells, suggesting that Notch and Hedgehog signaling may represent
therapeutic targets for PCSCs (105). Other studies have also implied alternative
mechanisms, including the NF-κB pathway (94), and miR-34a (96).

1.8. Studies of mouse PCSCs
There have been several reports on mouse PCSCs. For example, Sca-1+, but not Sca1- mouse prostate cells can lead to PIN after viral infection of AKT1, suggesting that Sca1+/AKT+/hi cells are endowed with high tumor-initiating capacity (33). A notable study from
Wu and colleagues demonstrated that a subset of PCa cells from PTEN-null models possess
heightened sphere-forming capacities and enhanced tumor-regenerative potentials,
compared to other subsets of cells, which can be enriched by the phenotypic markers of LinSca-1+CD49fhigh (LSC). Interestingly, tumors derived from LSC cells have been shown to
mimic their parental tumors (134). Another study has demonstrated protospheres from
PTEN/TP53 null mice are enriched in tumor-initiating cells with enhanced levels of AKT
and AR pathways in tumor growth, implying that these pathways may play roles in
regulating mouse PCSCs (135).
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1.9. Outline of Ph.D. projects: a brief overview
Although we and others have made significant contributions to identify and
characterize PCSCs in both human and mouse tumor models, many unresolved issues and
questions still exist. First, whether CSCs, in general, are resistant to chemo- and radiotherapies is controversial, let alone the murky relationship between PCSCs and therapy
resistance. In Chapter 2, I will present results from our model, in which we established
chronic drug-tolerant cancer cells from several cell lines (Du145, DLD1 and UC14), and
uncovered their CSC properties in vivo and in vitro. To our surprise, we found that not all
drug-tolerant cancer cells manifest CSC features. Second, the majority of our previous
studies of human PCSCs used cultured cell lines as well as xenograft tumors. Although there
is some evidence for the presence of PCSCs in primary HPCa patient samples, definitive
evidence is lacking due to the aforementioned challenge of using primary HPCa cells. In
Chapter 3, I will present data from our attempt to reconstitute PCa development in
immunodeficient mice using single HPCa cells. Finally, as the majority of advanced PCa
will eventually develop into the lethal and incurable CRPC, the mechanisms of CRPC
regulation are not clear, and the cell-of-origin for CRPC (or CaRP-CSCs) have not been
reported. In Chapter 4, I will present preliminary data from our in vivo and in vitro
characterizations to show that we have found putative CaRP-CSCs phenotypically
manifested by ALDH+CD44+α2β1+ (TM+). Our mechanistic studies of these cells are
currently ongoing, which will be one of our major projects in the future.
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Chapter 2

Drug-tolerant cancer cells show reduced tumor-initiating capacity:
depletion of CD44+ cells and evidence for epigenetic mechanisms
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2.1. Introduction
Therapy resistance is a common phenomenon in clinical cancer treatments. Most
existing therapies that have been developed result in initial tumor shrinkage. However, most
tumor treatments (e.g., chemo-, radio- and tumor-targeted agents) eventually fail, and
tumors relapse and metastasize. The exact mechanisms behind therapy resistance in cancer
are very complicated, and possible causes include: 1) ineffectiveness of therapy (e.g.,
delivery failure of the drug); 2) existence of therapy-resistant CSCs; 3) genetic and/or
epigenetic influence on tumor cells (136).
As introduced in Chapter 1, the CSC model has been gaining much interest and
attention, opening the possibility for more effective treatments against tumors. It is generally
believed that the more aggressive a tumor is, the more CSCs it may contain (137, 138), and
it is implied that such aggressive and advanced tumors tend to ultimately return (139). The
phenomenon where tumors initially regress after treatment but eventually recur suggests that
most existing therapies are likely to kill the bulk of tumor cells bearing limited proliferative
capacities, but leave behind the CSCs, which are responsible for long-term tumor growth
(6). Therefore, it is assumed that CSCs are therapy resistant. One corollary in support of this
assumption is the observations that CSCs can be enriched by therapeutic treatments. For
example, chemotherapy has been shown to increase breast CSCs (69). This, together with
other studies, implies that therapy-tolerant cancer cells may possess CSC properties (140),
although this assumption has not been rigorously examined.
What are the potential mechanisms regulating CSC therapy resistance? First, a large
body of evidence has postulated that the quiescent and slow cycling CSCs may be resistant
to therapy (49, 141), which has been exemplified in acute myeloid leukemia (AML) and
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some solid tumors (49). As mentioned earlier in Chapter 1, a recent study using pulse-chase
experiments (via CIdU and IdU, two BrdU analogues) have demonstrated the presence of a
subset of GFP+ glioma stem cells after TMZ treatments (126), providing strong support that
therapy-resistant CSCs are slow cycling and quiescent. Second, CSCs, like their normal
counterparts, may express high levels of ATP-binding cassette (ABC) drug efflux proteins.
SP has been a useful tool to isolate both normal SCs (142) and CSCs (86), whose phenotype
is mediated by ABC transporters associated with multidrug tolerance (143). Experimentally,
SP utilizes a FACS-based Hoechst dye 33343 staining protocol, in which SCs pump out the
dye, whereas the bulk of differentiated cells accumulate the dye, resulting in a small
population of cells expressing Hoechst-/lo in the Flow chart, known as ‘side population’ cells.
Because of this, it is believed that a similar trait is responsible for CSC drug tolerance.
Third, enhanced expression of anti-apoptotic genes has been observed in normal SCs as well
as CSCs. For example, a recent report has demonstrated that anti-apoptotic genes (i.e.,
CFLAR, Bcl-2, and Bcl2A1) are highly expressed in CSC-enriched SP populations in Ho-1N-1 cells, a human oral squamous cell carcinoma cell line (144). More importantly, Ho-1-N1 SP cells not only survive better than the non-SP cells after chemo- treatments (e.g., 5fluorouracil and carboplatin), but also have sharply higher anti-apoptotic activities,
providing direct evidence for anti-apoptotic mechanisms in chemotherapy resistance of
CSCs (144). Fourth, CSCs may be inherently resistant to certain stresses, including reactive
oxygen species (ROS), and DNA damage. For instance, mouse breast CSCs display lower
levels of ROS compared to the bulk of non-tumorigenic cancer cells, which confers CSCs
significantly higher clonogenic survival after ionizing radiation (145). In addition, treatment
with the glutathione synthesis inhibitor BSO dramatically inhibits the clonogenicity of these
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CSCs and increases their sensitivity to ionizing radiation (145). Another example comes
from glioma stem cells, in which CD133+ glioma stem cells are enriched after ionizing
radiation compared to CD133- glioma cells, and the radio-resistance is mediated by
enhanced activation of the DNA damage checkpoint in these CD133+ CSCs. Using specific
inhibitors of Chk1 and Chk2 kinases significantly inhibits these CSC survival after radiation
(73). These studies suggest that CSCs have an innate ability to resist many therapies.
However, it is still debated whether all CSCs are therapy-resistant and, vice versa,
whether drug-tolerant cancer cells possess CSC activities. For instance, testicular carcinoma
and choriocarcinoma are derived from germ cells that are driven by undifferentiated tumor
cells compared to the bulk of differentiated cells. However, both chemo- and radiotherapies tend to kill the undifferentiated portion, leaving the residual mass full of
differentiated cells (146). This suggests that some undifferentiated tumor cell populations, in
which CSCs are highly enriched, are sensitive to cancer therapies.
In PCa, the study of PCSCs and therapy tolerance is largely lacking. To address
whether PCSCs, like CSCs in other cancer types, bear resistance to chemo- and radiotherapy, or whether drug tolerant PCa cells are enriched in PCSCs, we conducted studies
presented herein. In our study, we created several lines of chronic ‘drug-tolerant cells’
(DTCs), and characterized their CSC properties: tumorigenicity and metastatic potential in
xenograft models, and also clonogenicity and proliferative capacities in vitro. We initially
hypothesized that DTCs in PCa are endowed with CSC traits both in vivo and in vitro.
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2.2. Materials and Methods
Animal-related studies have been approved by the M.D Anderson Cancer
Center Institutional IACUC committee (ACUF 08-05-08132). All other studies
presented herein were the investigator-initiated and did not require approval from
other regulatory bodies.
Cells, reagents, and animals
Du145, PC3, and UC14 cells were obtained from ATCC and cultured in
RPMI containing 7% heat-inactivated FBS, 100 µg/ml streptomycin, and 200 U/ml
penicillin (Gibco). DLD1 cells were obtained from ATCC and cultured in DMEM
containing 7% FBS with antibiotics. Etoposide (VP16) and paclitaxel were
purchased from Sigma. Doxorubicin (Dox) and staurosporine (STS) were bought
from Biomol. WP1102 and WP1103 were two newly synthesized paclitaxel analogs
with substitutions at the 2’-OH (by the Priebe group; details to be published
elsewhere). Primary antibodies used in the current study included: rabbit mAb to
CD44 (Abcam) for Western blotting (1:1,000), mouse mAb to CD44 (BD
Pharmingen) for immunostaining (1:500), mouse mAb to ABCG2 (Abcam; 1:500),
rabbit pAb to Bcl-2 (Santa Cruz; 1:500), mouse mAbs to p21 and p27 (Santa Cruz;
1:1,1000 for both), rabbit pAb to hTERT (Santa Cruz; 1:100), rabbit mAb to
GAPDH (Cell Signaling; 1:2,000) and mAb to β-actin (Cell Signaling; 1:1,000).
Secondary antibodies were purchased from GE Healthcare and ECL Plus reagents
were from PerkinElmer Inc. NOD/SCID mice were initially purchased from the
Jackson Laboratories (Bar Harbor, ME) and the breeding colonies established in our
animal facility and maintained in standard conditions according to the institutional
guidelines.
Establishment of DTCs and determination of IC50 values
Du145, DLD1, and UC14 cells were initially exposed to various drugs, in
quadruplicate wells, at a range of concentrations, i.e., 0, 0.1 nM, 1 nM, 10 nM, 50
nM, 0.1 µM, 0.5 µM, 1 µM, 2 µM, 4 µM, and 10 µM. Drugs were replenished every
3 days and cells were treated continuously for 2 weeks. Cell survival and death were
closely monitored under an inverted phase-contrast microscope. At the end of a 2week treatment, ‘optimal’ drug concentrations were determined based on the
criterion that drugs showed significant inhibitory effects on cell expansion but did
not completely kill the whole population (~90% cell killing). The entire experiment
was repeated once. These experiments led to the determination of optimal
concentrations. Thereafter, cancer cells were continuously cultured in the medium
containing the optimal concentration of drugs for a minimum of 3 months to
establish the DTCs, which were designated as Du145-VP16 cells, Du145-Paclitaxel
cells, so on and so forth. The DTCs were routinely cultured in the medium
containing the optimal concentrations of individual drugs.
To determine the half-maximal concentrations of inhibition (i.e., IC50) of
parental cancer cells and the DTCs, 2.5-3.0×105 cells were plated in quadruplicate in
24-well plates. After overnight culture, cells were treated with different
concentrations of the initial selection drug or non-selecting drugs (to examine
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potential cross resistance) for 24-48 h. At the end of treatment, viable cell numbers
were counted using trypan blue assays and the GraphPad prism 5.0 software was
used to analyze data and calculate the IC50 values.
Clonal and BrdU incorporation assays, immunofluorescence, and
immunoblotting
Basic procedures for these experiments have been described in our earlier
publications (80, 81, 85-87, 147). To determine total cell numbers, 5,000 cells were
plated in triplicate or quadruplicate in 12-well plates and cultured for 10 days, with
fresh medium fed every 3 days. At the end, viable cell numbers were counted using
trypan blue. For BrdU assays, cells were plated in triplicate on glass coverslips
(10,000 cells/coverslip) overnight and then pulsed with 10 µM BrdU for 4 h. At the
end, cells were fixed in 4% paraformaldehyde containing 5% sucrose for 10 minutes.
Cells were incubated for 20 min in 1% Triton-100 and then denatured, neutralized,
blocked, and incubated with monoclonal anti-BrdU antibody (1:100) for 1 h at 37°C
followed by goat anti-mouse IgGAlexa Fluor 594 (30 min at 37°C). A total of 500–
1000 cells were counted per coverslip and two coverslips were counted for each cell
type to determine the percentage of proliferating (i.e., BrdU+) cells.
For clonal analysis, 100 cells were plated in triplicate in 6-well plates and
cultured for 10 days with fresh medium fed every 3 days. At the end, both holoclones
and meroclones (82) were enumerated and the results were presented as the cloning
efficiency. Paraclones contained large and senescent cells (82) and generally had <20
cells and therefore were not quantified. Immunofluorescence staining of CD44 was
performed as described (85, 147). For Western blotting. parental Du145 and various
drug-tolerant Du145 cells were harvested to prepare whole cell lysate in Western
blotting analysis of the molecules indicated in the figure panels. In some
experiments, Du145-VP16 cells were first treated with various concentrations of
trichostatin A (TSA) or 5’-aza-deoxycytidine (Aza) for 72 h.
Establishment of GFP-tagged drug-tolerant DU145 cells
Briefly, 293FT packaging cells (80) were transfected with pLL3.7-GFP
lentiviral vector (80) together with the packaging plasmids using Lipofectamine.
Virus-containing medium was collected 48-72 h later, centrifuged at 3,000 rpm,
passed through a 0.45 µm filter to remove debris and finally subjected to
ultracentrifugation (20,000 rpm×2 h at 4°C). Drug-tolerant DU145 cells were then
infected with the virus at MOI (multiplicity of infection) of 20–25.
Subcutaneous (s.c) and orthotopic tumor experiments
Basic procedures were previously described (80, 82, 85-87, 96, 98). Briefly,
parental and drug-tolerant Du145 (and other) cells at different numbers were injected
in 50% Matrigel s.c into the flanks of NOD/SCID mice. When the largest tumor(s) in
any group must be terminated by IACUC regulations or the tumor-bearing animals
became moribund, all animals in that group were sacrificed and tumors harvested.
For orthotopic implantation, animals were anesthetized and cells were injected in a
40-µl medium-Matrigel mixture (1:1) into the dorsal prostate. When tumor burden
became obvious (by palpation), the experiment was terminated, animals sacrificed,
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and primary tumors together with several organs (i.e., lung, liver, spleen, pancreas,
kidney, etc) were dissected and examined for micro and macrometastasis (i.e., GFP+
foci) under a Nikon epifluorescence microdissection microscope.
CD44 knockdown experiments
shRNA-mediated knockdown was performed as recently described (80, 96).
Briefly, 293FT packaging cells were transfected with either pGIPz CD44-shRNA
lentiviral vector or pGIPz-NS control vector. The virus-containing culture medium
was collected 72 h post transfection, centrifuged at 3,000 rpm, filtered through a 0.45
µm-syringe filter, and finally subjected to ultracentrifugation (20,000 rpm×2 h at
4°C). The viral pellet was reconstituted in the OPTI-MEM medium and used to
infect HT1080 fibrosarcoma cells to determine the viral titer. Then Du145 cells were
infected with the pGIPz-NS or pGIPz-CD44shRNA viruses at an MOI of 20, and,
24–48 h later, were used in either in vitro characterizations or in vivo tumor
experiments.
CD44 overexpression experiments
The basic retroviral procedure was previously described (96). Briefly,
retroviral vectors, including control vector pBabe-GFP and pBabe-CD44 (Addgene,
Cambridge, MA) were transfected into the Ampho-Phoenix 293 cells (ATCC). 48–
72 h post transfection, virus-containing culture medium was collected, centrifuged at
3,000 rpm, filtered through a 0.45 µm-syringe filter, and finally subjected to
ultracentrifugation (22,000 rpm×2 h at 4°C). The viral pellet was reconstituted in the
OPTI-MEM medium and used to infect drug-tolerant Du145 cells for 24–48 h, which
were then used in both in vitro and in vivo experiments.
Therapeutic treatment of orthotopic PC3 tumors with paclitaxel
The basic procedure for therapeutic experiments was recently described (96).
Briefly, PC3-GFP cells were implanted in the dorsal prostate (DP) of male
NOD/SCID mice (500,000 cells/DP; n =10). Three weeks later, 5 animals per group
were injected, intravenously, with 15 mg/kg body weight of paclitaxel or vehicle
control (PBS). The injections were repeated every week for two more weeks (i.e., a
total of 3 injections) and animals were terminated 49 days after tumor cell
implantation. The DP tumors were dissected out, imaged, and weighed whereas
several organs, including the lung, pancreas, lymph node, liver, and brain, were
examined for metastasis on a dissecting epifluorescence microscope (96).
Analysis of ‘stemness’ gene expression profiles by quantitative reverse
transcriptase - polymerase chain reaction (qPCR)
The basic procedure for qPCR analysis was recently described (81, 96).
Briefly, total RNA was extracted from Du145 and Du145-VP16 cells using an
RNeasy RNA-purification kit (Qiagen, Valencia, CA). The ABI High-Capacity
cDNA Archive Kit (Applied Biosystems, Carlsbad, CA) and random hexamers were
used for cDNA synthesis. qPCR was performed by the M.D. Anderson Science-Park
Molecular Biology Core Facility using an ABI Prism 7900HT (Applied Biosystems).
File Builder 3.1 software (Applied Biosystems) was used to design PCR primers and
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probes. Human gene-specific primer pairs were used for expression profiling by the
SYBR® Green method. The experimental Ct (cycle threshold) was calibrated against
that of 18S control product. All amplifications were performed in triplicate. The
DDCt method was used to determine the amount of gene product relative to that
expressed in parental Du145 cells (1-fold, 100%).
Statistical analyses
GraphPad prism 5.0 software and F-test were used to compare the IC50
values. Unpaired t-test was used to compare differences in cell numbers, BrdU+%
cells, cloning efficiency, CD44+% cells, and tumor weights. Fisher’s Exact Test was
used to compare incidence and latency.
(The above Methods and Materials were taken from (148) with all authors’
permission)
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2.3 Results
Chronic sublethal drug treatment led to drug-tolerant cancer cells
Clinically, many cancer patients are often treated CHRONICALLY by anticancer therapeutics. The best example perhaps is CML (chronic myelogenous
leukemia) patients who must take imatinib (Gleevec) continuously for years (149).
Furthermore, metronomic chemotherapy - a form of chemo administration
characterized by frequent, often daily, extended administration of small doses of
conventional chemodrugs without major breaks (150), is emerging as a standard
therapeutic regimen for many cancers. Based on the assumptions that CSCs may
have a special advantage of surviving therapeutics and are likely the cells that
mediate drug resistance, we tested whether cancer cells that have survived
CHRONIC drug treatment may all possess CSC properties. We first treated Du145
prostate cancer (PCa) cells with two clinical drugs, i.e., etoposide (VP16) and
paclitaxel (Taxol) as well as three experimental drugs, staurosporine (STS), a
promiscuous protein kinase inhibitor, and two newly synthesized paclitaxel analogs
termed WP1102 and WP1103. As described in Methods, we first treated Du145 cells
with these five drugs at a range of 10 concentrations for 2 weeks to determine the
‘optimal’ sublethal concentrations at which drugs significantly inhibited tumor cell
expansion but did not kill the entire population. Using this chronic treatment protocol
that ‘mimics’ metronomic treatment in the clinic, we determined the optimal
concentrations, in Du145 cells, of VP16, paclitaxel, STS, WP1102, and WP1103 at
1.25 µM, 50 nM, 7 nM, 5 nM, and 25 nM, respectively. Du145 cells were
subsequently cultured, continuously, in the medium containing the optimal
concentrations of drugs for ~3 months. The resultant drug-tolerant cell (DTC) lines
were designated as Du145-VP16, Du145-Paclitaxel, Du145-STS, Du145-WP1102,
and Du145-WP1103 cells, respectively.
To determine whether drug-tolerant Du145 cells were truly tolerant of the
original selection drugs, we treated parental and drug-tolerant Du145 cells side-byside with the respective five drugs. As shown in Figure 2-1, drug-tolerant Du145
cells were generally more resistant than parental Du145 cells to the selection drugs.
Thus, Du145-VP16 cells were >10 times more resistant than Du145 cells to VP16
(IC50 values being 0.78 µM for Du145 and 9.17 µM for Du145-VP16 cells). Du145Paclitaxel cells were ~7 times more resistant to paclitaxel than Du145 cells (Figure
2-1, A and C). Similarly, Du145-WP1103 cells were nearly 30 times more resistant
to WP1103 than Du145 cells (Figure 2-1, B and C). Finally, Du145-STS and Du145WP1102 cells were approximately 1.5 and 3 times more resistant to STS and
WP1102, respectively, than unselected Du145 cells (Figure 2-1, B and C). Hence,
the differential drug resistance among the established DTCs ranked Du145WP1103>Du145-VP16>Du145-Paclitaxel>Du145-STS≈Du145-WP1102.
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Figure 2-1. Drug-tolerant Du145 cells were more resistant to the selection drugs.
A-B. Parental Du145 and drug-tolerant Du145 cell lines selected with two clinical
drugs (A) or three experimental drugs (B) were exposed, side-by-side, to the
respective selection drugs (e.g., Du145-VP16 cells to VP16 and Du145-Paclitaxel
cells to paclitaxel) at the concentrations (transformed into logarithm) indicated. Yaxis represents cell growth inhibition (%). C. Tabulated presentations of IC50 values
and corresponding 95% CI (confidence interval) of Du145 cells and drugs-tolerant
Du145 cells in response to the five drugs indicated. Values were calculated from data
obtained in A and B. Taken from (148) with all authors’ permission.
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Subsequently, we exposed Du145-VP16 cells to three non-selecting drugs,
i.e., paclitaxel, STS, and doxorubicin (Dox). As shown in Figure 2-2, Du145-VP16
cells were more resistant (than parental Du145 cells) to paclitaxel (~4 fold), STS (1.5
fold), and Dox (13 fold), suggesting that the DTCs were also cross-resistant to other
non-selecting drugs.
Using similar strategies, we also established drug-tolerant DLD1 colon
(Figure 2-3) and UC14 bladder (data not shown) cancer cells. In DLD1 cells, the
optimal concentrations for VP16, paclitaxel, WP1102, and WP1003 were determined
to be at 2.5 µM, 100 nM, 120 nM, and 100 nM, respectively. As shown in Figure 23, the established DLD1-VP16, DLD1-Paclitaxel, DLD1-WP1102, and DLD1WP1103 cells were resistant to the respective selecting drugs. Furthermore, DLD1VP16 cells also showed cross resistance to paclitaxel and Dox (Figure 2-3B). Drugtolerant UC14 cells were similarly more resistant to the selection drugs (i.e.,
paclitaxel, STS, VP16, Dox, WP1102, and WP1103), than the parental UC14 cells
(data not shown).
Drug-tolerant Du145 cells were surprisingly less tumorigenic than parental
Du145 cells
We initially hypothesized that the DTCs might possess CSC properties and
be more tumorigenic in vivo. Much to our surprise, all drug-tolerant Du145 cells
subcutaneously (s.c) injected into the NOD/SCID mice demonstrated much reduced
tumor-initiating capacity when compared to the same number of parental Du145
cells, which showed a tumor-initiating frequency (TIF) of ~1/175 (Table 2-1).
Injection of increasing numbers of parental Du145 cells, expectedly, led to reduced
latency (Table 2-1). In contrast, Du145-VP16 cells showed a TIF of ~1/62,000 and,
at 100,000 cells injected, tumor latency was more than twice as long as for the same
number of Du145 cells (Table 2-1). In fact, both Du145-Paclitaxel and Du145WP1103 cells were non-tumorigenic up to 10,000 (for Du145-WP1103) and 100,000
(for Du145-Paclitaxel) cells implanted (Table 2-1). Even for Du145-STS and Du145WP1102 cells, which showed the lowest IC50 differentials (Figure 2-1 B and C),
reduced tumor incidence with TIF of 1/971 and 1/45,787, respectively, and smaller
tumors were also observed (Table 2-1).
To determine whether tumor implantation site might have an effect on the
differential tumorigenicity observed, we established GFP-tagged Du145 parental and
drug-tolerant Du145 cells and implanted equal numbers (i.e., 500,000) of cells
orthotopically in the dorsal prostate (DP) of the male NOD/SCID mice. When the
experiment was terminated 75 days post tumor cell injections, we observed that
Du145-VP16 and Du145-STS cells generated smaller tumors than parental Du145
cells (Figure 2-4A). In fact, both Du145-Paclitaxel and Du145-WP1103 cells were
non-tumorigenic in the DP tumor regeneration model (Figure 2-4A). Significantly,
parental Du145 cells metastasized to multiple organs including lymph nodes, kidney,
pancreas, liver, lung, and spleen whereas drug-tolerant Du145 cells lacked apparent
metastasis to any of these organs (Table 2-2; Figure 2-4; data not shown).
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Figure 2-2. Drug-tolerant Du145 cells were cross-resistant to non-selecting
drugs. Du145-VP16 cells were treated with paclitaxel (A), STS (B), and doxorubicin
(Dox; C) at the concentrations [log] indicated. Results are presented as % inhibition
and IC50 (D) were determined as in Figure 2-1. Taken from (148) with all authors’
permission.
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Figure 2-3. Drug-tolerant DLD1 cells were resistant to selecting and nonselecting drugs. Parental and drug-tolerant DLD1 cell lines selected with optimal
concentrations of VP16, paclitaxel, WP1102, and WP1103, were exposed, side-byside, to the respective selection drugs at the concentrations (transformed into
logarithm) indicated (A). Y-axis represents cell growth inhibition (%). B. Tabulated
presentations of IC50 values and corresponding 95% CI (confidence of intervals) of
parental DLD1 cells and drug-tolerant DLD1 lines in response to both selecting and
non-selecting drugs. Taken from (148) with all authors’ permission.
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Table 2-1. Drug-tolerant Du145 cells possess much reduced tumorigenic
potential. aParental Du145 or drug-tolerant Du145 cells were s.c implanted in 50%
Matrigel, at the numbers indicated, in NOD/SCID mice. In the two experiments
marked by #, cells were first cultured in drug-free medium for 2 months prior to
injections. bTumor incidence (% of tumor development/injections). cTumor-initiating
frequency, as determined using the L-CalcTM software (Stemcell Technologies). The
ranges were indicated in the parentheses. dTumor latency (mean time in days from
injection to when tumors were first palpated) and termination time (days from
injection to when animals were sacrificed). eMean ± S.D (ranges in parentheses).
Note that tumor weights sometimes varied greatly among different cell number
groups. For statistical analyses, Fisher’s Exact Test was used to compare tumor
incidence and Student t-test was used to compare tumor weights and latencies. *P<
0.05; **P<0.01, when compared with the parental Du145 cells of the same number.
Taken from (148) with all authors’ permission.
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Table 2-2. Reduced tumorigenic potential of orthotopically implanted drugtolerant Du145 cells. GFP-tagged parental or drug-tolerant Du145 cells were
implanted (500,000 cells/injection), in 50% Matrigel, in the DP of NOD/SCID mice.
All animals were terminated 75 days post implantation. Shown are tumor incidence
and tumor weights (mean ± S.D; statistics not applicable due to relatively small
numbers of animals). Adapted from (148) with all authors’ permission.
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Figure 2-4. Orthotopically implanted drug-tolerant Du145 cells showed reduced
tumorigenic and metastatic potential. Representative tumor and organ images
from a tumor-bearing animal in the Du145 (A) and Du145-VP16 (B) group,
respectively. All images were acquired using a Nikon microdissecting
epifluorescence microscope at 0.75× and the boxed area in A (the lung GFP image)
represents an enlargement showing GFP+ spots in the lung. Adapted from (148) with
all authors’ permission.
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Drug-tolerant DLD1 cells also showed reduced tumorigenicity whereas drugtolerant UC14 cells demonstrated drug-dependent changes in tumor initiating
capacity
To determine whether the reduced tumorigenicity associated with drugresistant cells is restricted only to Du145 cells, we similarly injected, s.c., increasing
numbers of parental DLD1 and four drug-tolerant DLD1 cell lines into the
NOD/SCID mice. As shown in Table 2-3, the drug-tolerant DLD1 cells, though
displaying similar tumor incidence, regenerated significantly smaller tumors
compared to parental DLD1 cells at the same cell numbers.
We carried out similar limiting-dilution tumor experiments in 6 drug-selected
UC14 cells (Table 2-4). In contrast to drug-tolerant Du145 and DLD1 cells, which
uniformly demonstrated reduced tumorigenic potential, 4 of the 6 drug-tolerant
UC14 cells (Table 2-4; shadowed brown) demonstrated enhanced tumorregeneration capacity compared to the same number of parental UC14 cells.
Interestingly, two drug-tolerant UC14 cell lines also regenerated much smaller
tumors than the same number of parental UC14 cells (Table 2-4; shadowed pink).
These results indicate that drug-tolerant UC14 cells are either more or less
tumorigenic than the parental cells, depending on the initial selection drugs.
Drug-tolerant Du145 cells were less proliferative and showed low cloning
efficiency
Since it was quite unexpected that some drug-tolerant cancer cells showed
reduced tumor-regenerating capacity, we subsequently focused on drug-tolerant
Du145 cells in attempt to uncover potential mechanisms. We consistently observed
that most drug-tolerant Du145 cells seemed to proliferate more slowly compared to
Du145 cells. Indeed, in a prospective 10-day experiment measuring live cell
numbers, we observed that all drug-tolerant Du145 cells, except Du145-WP1102
cells, showed much lower end-point live cell numbers (Figure 2-5A), suggesting that
DTCs were less proliferative and/or more susceptible to cell death. We then carried
out BrdU incorporation experiments to directly measure cell proliferation. As shown
in Figure 2-5B, drug-tolerant Du145 cells exhibited lower proliferative indices (i.e.,
% BrdU+ cells). Interestingly, even Du145-WP1102 cells demonstrated a lower
proliferative index (Figure 2-5B) although these cultures showed similar total live
cell numbers to parental Du145 cells (Figure 2-5A). Remember that Du145-WP1102
cells also displayed relatively less reduction in tumor-initiating capacity compared to
other drug-tolerant Du145 cells (Table 2-1). It is possible that Du145-WP1102 cells
proliferated less but also had less spontaneous cell death, thus resulting in similar
end-point live cell numbers (Figure 2-5A) and less pronounced decreases in
tumorigenicity (Table 2-1). Indeed, we consistently observed that Du145-WP1102
cells, chronically selected using 5 nM WP1102 compound, showed less floating and
apoptotic cells in the culture flasks compared with Du145-WP1103 cells (not
shown), which were chronically selected using 25 nM WP1103 compound. Finally,
we observed that all drug-tolerant Du145 cells demonstrated lower cloning
efficiencies than the parental Du145 cells (Figure 2-5C).
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Table 2-3. Reduced tumorigenic potential in drug-tolerant DLD1 cells. Parental
or drug-tolerant DLD1 colon cancer cells were implanted, in 50% Matrigel, at
various cell numbers s.c in NOD/SCID mice. Presented are tumor incidence (%
tumor development), termination time (days since tumor cell injection when animals
were sacrificed), and tumor weights (mean ± S.D; ranges in parentheses). *P< 0.05
and **p<0.01, compared with the parental DLD-1 cells of the same numbers. Taken
from (148) with all authors’ permission.
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Table 2-4. Drug-tolerant UC14 cells demonstrate drug-dependent changes in
tumorigenicity. aParental UC14 or drug-tolerant UC14 cells were implanted s.c, in
50% Matrigel, at the numbers indicated, in NOD/SCID mice. bTumor incidence (%
of tumor development/injections). Δ, P< 0.05, compared with UC14 at the same cell
dose. cTumor latency refers to mean time in days from injection to when tumors
were first palpated. Δ, P< 0.05, and ΔΔ, P<0.01, when compared with UC14 at the
same cell doses. All animals injected with the same number of tumor cells were
terminated at the same time. dMean ± S.D (ranges in parentheses). *, P< 0.05, and
**, P<0.01, compared with UC14 at the same cell doses. For statistical analyses,
Fisher’s Exact Test was used to compare tumor incidence and latency and Student ttest was used to compare tumor weights and latencies. Taken from (148) with all
authors’ permission.
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Figure 2-5. Drug-tolerant Du145 cells were less proliferative and showed low
cloning efficiency. (A). Quantification of numbers of viable cells. Parent and drugtolerant Du145 cells were plated, in quadruplicate, in 12-well plates (5,000
cells/well) and viable cells were quantified using Trypan blue exclusion assay 10
days post plating. (B). Quantification of % BrdU+ cells. (C). Determination of
cloning efficiency. Parent and drug-tolerant Du145 cells were plated, in
quadruplicate, in 6-well plates (100 cells/well) with fresh medium replenished every
3 days. The numbers of holoclones and meroclones were determined 10 days post
plating. In all data, bars represent the mean ± S.D and statistical analyses were
conducted using Student t-test (*, P<0.05; **, P<0.01). Taken from(148) with all
authors’ permission.
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Consistent with reduced cell proliferation, drug-tolerant Du145 cells showed
increased levels of two cyclin-dependent kinase inhibitors, p21 and p27, especially in
Du145-Paclitaxel and Du145-WP1103 cells (Figure 2-6A), the two cell lines that
completely lacked tumorigenicity (Table 2-1). The p27 levels were also elevated in
all three other drug-tolerant Du145 cell lines (Figure 2-6A). Intriguingly, the
significantly increased p27 protein band in Du145-Paclitaxel and Du145-WP1103
cells migrated slightly faster than the protein in other cell lines (Figure 2-6A). Future
studies will clarify this potentially interesting observation. In contrast to p21 and
p27, Bcl-2, an anti-apoptotic protein, showed less, albeit dramatic decrements, again,
in the two non-tumorigenic Du145 lines, i.e., Du145-Paclitaxel and Du145-WP1103
(Figure 2-6A).
Drug-tolerant Du145 cultures showed reduced numbers of, or were devoid of,
CD44+ cells
Several pieces of evidence suggest that diminished tumor-regenerating
capacity in drug-tolerant Du145 cells may involve, in addition to compromised
proliferative potential perhaps mediated by increased p21 and p27, drug-induced
defects in tumor-initiating cells. When we examined drug-tolerant Du145 cells for
the levels of hTERT, which is essential for normal prostate stem/ progenitor cells as
shown by our recent studies (147), we found that Du145-Paclitaxel and Du145WP1103 cells, which lacked tumorigenic potential, lost hTERT expression (Figure
2-6A). Our previous studies have demonstrated that the clonogenic and tumorigenic
potential of Du145 cells largely resides in the CD44+ cell fraction (15, 85) and it has
recently been shown by one of our groups that paclitaxel conjugated to hyaluronic
acid, designed to specifically target the CD44-expressing cells, exhibited potent antiovarian cancer effects (151).
The above discussions raised the possibility that perhaps CD44+ cells and/or
CD44 expression were reduced or ablated in drug-tolerant Du145 cell lines. To test
this possibility, we carried out both Western blotting and immunofluorescence
experiments. Remarkably, both Du145-Paclitaxel and Du145-WP1103 cultures
completely lacked CD44+ cells (Figure 2-6; Figure 2-7; Figure 2-8). Du145-VP16
and Du145-STS cultures also showed reduced CD44 protein levels (Figure 2-6) and
numbers of CD44+ cells (Figure 2-6; Figure 2-7; Figure 2-8). By contrast, Du145WP1102 cells, which retained some tumor-initiating capacity (Table 2-1), showed
similar levels of CD44 protein expression to (Figure 2-6B) or slightly more CD44+
(many faintly positive) cells (Figure 2-7; Figure 2-8) than parent Du145 cultures.
Hence, the extent to which CD44+ cells were ablated in drug-tolerant Du145 cultures
appeared to correlate well with the level of reduction in their tumorigenic potential.
In contrast to CD44, ABCG2 protein (Figure 2-6) or ABCG2+ cells (data not shown),
which constituted ~1% of total Du145 cells (86), did not show consistent and
significant changes in drug-tolerant Du145 cells.
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Figure 2-6. Western blotting of different molecules in drug-tolerant Du145 cells
cultures. (A). Whole cell lysate from the cell types indicated was used in Western
blotting of p21, p27, Bcl-2, and hTERT and the blot was reprobed for β-actin. NS,
non-specific. (B). Analysis of CD44 and ABCG2. The blot was reprobed for β-actin
and GAPDH. Adapted from (148) with all authors’ permission.
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Figure 2-7. Representative images of immunofluorescent staining of CD44 in
drug-tolerant Du145 cells cultures. Du145 and drug-tolerant Du145 cells were
plated on glass coverslips and stained for CD44 using monoclonal antibody. Adapted
from (148) with all authors’ permission.
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Figure 2-8. Quantification of CD44+ cells in drug-tolerant Du145 cells cultures.
The quantification was based on IF staining in Figure 2-7. Adapted from (148) with
all authors’ permission.

48	
  
	
  

Requirement of CD44 in Du145 cell tumorigenicity
The above surprising finding that drug-induced reduction/loss of CD44+ cells
correlates with reduction/loss of tumorigenic potential in Du145 DTCs, is fully
consistent with our earlier studies showing that the CD44+ PCa cells are more
tumorigenic and metastatic than the corresponding CD44- cells (85, 87). To
prospectively determine whether CD44 is causally involved in PCa cell
tumorigenicity, we infected parental Du145 cells with a lentiviral vector encoding
CD44 shRNA (CD44-shRNA) or a nonsilencing shRNA (NS-shRNA). CD44shRNA reduced CD44 protein (Figure 2-9A, inset) and inhibited Du145 cell
proliferation as evidenced by reduced % of BrdU+ cells (Figure 2-9A–B) resulting in
reduced live cell numbers (Figure 2-9C). When implanted either s.c or
orthotopically, the CD44-shRNA infected Du145 cells generated significantly
smaller tumors (Figure 2-10).
We then performed the reciprocal gain-of-function experiments by
overexpressing CD44 in drug-tolerant Du145 cells. Specifically, we infected the
Du145-VP16 cells with pBabe-CD44, which led to increased CD44 expression
compared to Du145-VP16 cells infected with pBabe-GFP (Figure 2-11, inset). CD44
re-expression in Du145-VP16 cells enhanced cell proliferation as revealed by BrdU
incorporation assays (Figure 2-11), resulting in increased live cell numbers (Figure
2-11). Pilot studies indicated that CD44 overexpression in Du145-VP16 slightly
increased tumorigenicity (tumor incidence was 1/4 vs. 4/6 in Du145VP16/pBabe.GFP and Du145-VP16/pBabe.CD44, respectively).
The above results suggest that a reduction in CD44+ cells is, at least partially,
involved in the reduced tumorigenicity of drug-tolerant Du145 cells. These
observations also imply that conventional drugs such as etoposide and Taxol may
directly target tumor-initiating cells. To further explore this latter point, we
employed PC3 cells, which are all CD44+ (85), to establish orthotopic tumors in the
mouse prostate. After tumors developed for ~3 weeks, we then performed a
therapeutic experiment via i.p (intra-peritoneal) injection of paclitaxel. Consistent
with the idea that Taxol may directly target CD44+ PCa cells, the intravenously
injected paclitaxel greatly inhibited PC3 tumor growth (Figure 2-12A) as well as
metastasis to the lung (Figure 2-12B), pancreas and many other organs (data not
shown).
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Figure 2-9. CD44 knockdown in Du145 cells and in vitro characterizations.
Du145 cells infected with the control (NS) or CD44 shRNA lentivectors (MOI 20;
72 h) were plated (10,000/well) in triplicate, pulsed by BrdU for 4 h, and processed
for BrdU staining. Shown in (A) is the quantification of BrdU+ cells from a total of
500 cells counted for each and in (B) are representative images (×400). Inset,
Western blot showing reduced CD44 protein expression in Du145 cells infected with
CD44-shRNA (lane 2) compared with the cells infected with NS-shRNA (lane 1).
For experiments in C, Du145 cells infected with the control (NS) or CD44
lentivector were plated (5,000/well) in quadruplicate on day 0. At the end of day 2, 4,
6, and 8, cells were dissociated and counted by Trypan blue exclusion. Plotted are
the live cell numbers (mean ± SD) as a function of time. *P = 0.019; **P = 0.003
(Student’s t-test). Adapted from (148) with all authors’ permission.
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Figure 2-10. CD44 knockdown in Du145 cells and in vivo characterizations. (A)
Shown are the weights (above; mean ± s.d, *P < 0.05) and images (below; incidence,
5/5 for both groups) of subcutaneous tumors derived from Du145 cells infected with
NS-shRNA or CD44-shRNA (MOI 20, 72 h; harvested at 56 d). (B) Shown are the
weights (above; mean ± s.d) and images (below) of orthotopic tumors derived from
Du145 cells infected with NS-shRNA or CD44-shRNA (harvested at 41 d). Tumor
incidence for the NS-shRNA and CD44-shRNA group was 7/7 and 5/8, respectively.
Adapted from (96) with permission from Nature Publishing Group.
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Figure 2-11. CD44 overexpression in Du145 cells and in vitro characterizations.
Du145-VP16 cells infected with GFP or CD44 retroviral vectors (MOI 20; 72 h)
were plated (10,000/well) in triplicate, pulsed by BrdU for 4 h, and processed for
BrdU staining. Shown in (A) is the quantification of BrdU+ cells from a total of 500
cells counted for each condition and in (B) are representative images (×400). Inset,
Western blot showing increased CD44 protein expression in Du145-VP16 cells
infected with pBabe-CD44 (lane 2) compared with the cells infected with pBabeGFP (lane 1). For experiments in C, Du145-VP16 cells infected with the GFP or
CD44 retroviral vectors were plated (5,000/well) in quadruplicate on day 0. At the
end of day 2, 4, 6, and 8, cells were dissociated and counted by Trypan blue
exclusion. Plotted are the live cell numbers (mean ± SD) as a function of time. *P =
0.035; **P = 0.028. Adapted from (148) with all authors’ permission.
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Figure 2-12. Paclitaxel inhibits PC3 orthotopic tumor growth and metastasis.
Presented in (A) is the tumor weight (mean ± S.D; n = 5 for each group). Tumor
incidence is the same (i.e., 5/5) for both groups. Shown in (B) are representative
phase and GFP microphotographs of lung metastases, i.e., GFP+ foci. Adapted from
(148) with all authors permission.
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Gene expression changes in drug-tolerant Du145 cells
To further understand what molecular changes might have occurred in drugtolerant cells, we performed a stem cell SuperArray gene expression analysis of ~20
‘stemness’ genes, including ALDH1A1 (the major isoform that mediates the
Aldeflour phenotype), BCL-2, CD24, CD29 (integrin β1), CD44, CD49b (integrin
α2), c-KIT, CSF-1R, CXCR4, ITGB3 (integrin β3), NANOG, NKX3.1, OCT-4,
PROM-1 (CD133), SOX2, hTERT, TGFB1, TGFBR2, and WNT4, in Du145 and
Du145-VP16 cells. Consistent with our Western blotting and immunostaining results
(Figure 2-6), CD44 mRNA was significantly lower in Du145-VP16 cells. The
mRNA levels of c-KIT and TGFBR2 were also significantly reduced (Figure 2-13).
The mRNA levels of NANOG and CSF-1R showed a reducing trend but the decrease
was not statistically significant. Most surprisingly, 6 molecules analyzed,
ALDH1A1, BCL-2, CXCR4, OCT-4, SOX2, and WNT4, showed significantly
increased mRNA levels in Du145-VP16 cells (Figure 2-13). These results indicate
that the drug-tolerant PCa cells show both decreases and increases in ‘stemness’
genes.
Evidence for epigenetic mechanisms in generating DTCs
Recently, it has been reported that while modeling the acute response of
human lung cancer cells to chemotherapeutic drugs, a small population of reversibly
drug-tolerant cells that possessed an altered chromatin state that involved the
KDM5A histone lysine demethylase can be detected (152). To determine whether
our DTCs were ‘permanently’ changed by chronic drug exposure, we cultured
Du145-VP16 and Du145-WP1103 cells in drug-free (DF) medium for 2 months and
performed tumor experiments. Such DF-2 month ‘reversion’ experiments revealed
that Du145-VP16 cells were still much less tumorigenic and Du145-WP1103 cells
still failed to regenerate tumors (Table 2-1, marked by #; Figure 2-14A). However,
when we cultured the Du145-VP16 cells in DF medium for 3 months and injected
10,000 such cells into the NOD/SCID mice, we observed 6/8 tumors (Figure 2-14A)
with mean tumor weight of 0.76 ± 0.24 g, of which both tumor incidence and weight
were close to those in the parental Du145 cells (Table 2-1). The above tumor
experiments suggest that the reduced tumorigenicity of drug-tolerant Du145 cells is
reversible and may also involve epigenetic mechanisms. To explore this point, we
treated Du145-VP16 cells with HDAC (histone deacetylase) inhibitor TSA
(trichostatin A) or DNA methyltransferase inhibitor 5’-aza-deoxycytidine (Aza), as
we previously described (80). Both treatments significantly increased the protein
levels of CD44, E-cadherin, and KDM5A (Figure 2-14B and C). When we injected
10,000 Aza-treated Du145-VP16 cells, we observed 3/10 tumors (Figure 2-14A).
These results thus implicate epigenetic mechanisms in chronic drug-induced DTC
generation.
(The above results were adapted from (148) with all authors’ permission)
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Figure 2-13. ‘Stemness’ gene expression profiles in Du145-VP16 cells. Du145VP16 cells show both decreases and increases in stemness gene expression levels.
The mRNA levels of the indicated genes in parental Du145 (set at 1, blue bars) and
Du145-VP16 (red bars) cells were determined by qPCR. P values were indicated for
those genes that showed statistically significant differences. Adapted from (148) with
all authors’ permission.
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Figure 2-14. Epigenetic mechanisms in Du145-VP16 cells. (A) Tumor incidence in
various types of Du145-VP16 cells implanted (10,000) in NOD/SCID mice. As
shown in Table 2-1, parental Du145 cells showed 100% incidence at 10,000 cells
whereas Du145-VP16 cells failed to initiate tumors. When cultured in drug-free (DF)
medium for 2 and 3 months, increased tumor incidence was observed (**P < 0.01
compared with Du145-VP16). When Du145-VP16 cells treated with Aza (0.1 µM,
72 h) were injected, increased tumor incidence was also observed (*P < 0.05 when
compared with Du145-VP16 cells). (B-C). Du145-VP16 cells treated with the
indicated chemicals (72 h) were used in Western blotting analysis of CD44,
KDM5A, and E-cadherin. β-Actin was used as loading control. UT: untreated.
Adapted from (148) with all authors’ permission.
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2.4. Discussion
The correlation of PCSCs and therapy tolerance is largely unknown. Many previous
studies of CSCs and therapy resistance in other tumor systems have shown that CSCs appear
to resist chemo- and radio- therapy, whereas therapy resistant cancer cells possess enhanced
CSCs properties (73, 145). However, in nearly all these studies, cancer cells were treated
with these therapies for only a few days, or at most 2 weeks, which only represents a shortterm drug tolerant state. In our current study, after chronic (>3 months) selection using 5
chemotherapy drugs (i.e., two clinical drugs: VP16 and Taxol; and three experimental drugs:
STS, WP1102, and WP1103), we have established several lines of DTCs from 3 different
tumor types: Du145 (prostate), DLD1 (colon) and UC14 (bladder). Contrary to previous
findings that therapy-resistant cancer cells may possess enhanced CSC properties and to our
initial hypothesis that DTCs in PCa may be enriched in CSCs, we have obtained somewhat
different and intriguing findings, which I will discuss below.
Firstly, most of our DTCs show decreased CSC properties manifested as diminished
proliferative, clonogenic, tumorigenic and metastatic potentials. For instance, all Du145DTCs are much less tumorigenic than parental Du145 cells, and, in fact, both Du145paclitaxel and Du145-WP1103 cells are nearly non-tumorigenic. Similarly, all DLD1-DTCs
generate much smaller tumors than the parental DLD1 cells. In contrast, 2 out of the 6
UC14-DTCs (UC14-Dox and UC14-VP16) generate much smaller tumors than the same
number cells from parental UC14 cells. However, the remaining 4 drug-tolerant cell lines
show enhanced tumorigenic potential, which is consistent with the general assumption that
therapy-resistant cells possess CSC properties (6). Consequently, we have focused on Du145
PCa cells for functional and mechanistic studies. Collectively, our results suggest that not all
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DTCs are CSCs, and some DTCs may manifest greatly reduced CSC activity both in vivo
and in vitro. On a facial value, our observations are consistent with reports that some CSCs
or CSC activities can be targeted and eradicated by certain therapies. For example, a recent
study, using a high- throughput chemical compounds screening (~16,000 compounds),
identifies salinomycin to specifically target breast CSCs (CD44+CD24-) that seem to be
intrinsically chemotherapy resistant (153). The therapeutic effects of salinomycin on the
breast CSCs are much more significant (>100-fold) compared to paclitaxel, a clinical anticancer drug for breast cancer. As a result, salinomycin reduced mammosphere formation as
well as tumor regenerative and metastatic potentials (153). Another study has shown that at
an optimized concentration, TMZ, a common chemotherapeutic agent for glioblastoma can
directly target CD133+ glioma stem cells and significantly inhibit their clonogenicity and
tumor-initiating capacities (154). Similar anti-CSC activities have also been reported in
other cancer types (155-158). Interestingly, docetaxel-resistant Du145 and 22Rv1 cells after
a 9-month and 6.5-month drug selection, respectively, appear to contain enhanced tumorinitiating ability (105), which suggests that whether DTCs contain CSCs is likely to be celland drug- dependent phenomenon.
Secondly, we have noticed that most of the chemotherapeutic reagents we studied
can eliminate CD44+ cells and that the reduced levels of CD44 correlate well with the
decreased levels of tumorigenicity and clonogenicity in our DTCs. Thus, both Du145Paclitaxel and Du145-WP1103 cells completely devoid of CD44+ cells display nontumorigenic properties. Du145-VP16 and Du145-STS cells that have partially depleted their
CD44+ cells exhibit partially reduced tumorigenicity and clonogenicity. In contrast, Du145WP1102 cells that appear to have stable or slightly higher levels of CD44, remain somewhat
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tumorigenic. These data in Du145-DTCs strongly suggest that CD44 may play a causal role
in the clonogenicty and tumorigenicity of PCa cells. To support this notion, we have
performed a CD44 knockdown experiment in several PCa cells lines (PC3, Du145, LAPC9,
etc), and observed that knocking down CD44 expression significantly inhibits tumor growth,
metastasis and sphere formation in these cells (96). In reciprocal experiments,
overexpression of CD44 can enhance the proliferative and tumorigenic potentials in some
Du145-DTCs. In summary, our current study further substantiates the importance of CD44
in regulating PCa development and PCSC activities. However, we have not yet found a
similar reduction of CD44 levels in DLD1 cells (unpublished data), implying that
chemotherapy-induced reduction of CD44+ cancer cells may be cell type-dependent. The
reason that DLD1-DTCs manifest reduced tumorigenicity is likely related to other
mechanisms that need future clarification.
Thirdly, we have noted both increased and decreased levels of SC-related genes in
DTCs, and the state of drug tolerance seems to be ‘reversible’, which implies some
epigenetic mechanisms in generating DTCs. For example, we cultured the Du145-DTCs in
drug free medium for ~2-3 months before conducting a limiting dilution tumor experiment.
Initially, Du145-VP16 cells continuously cultured in VP16-containing medium were nontumorigenic at 10,000-cell injection. However, the same cells cultured in VP16-free medium
gradually regained their tumorigenicity, with tumor incidence of 1/6 and 6/8 if cultured at 2
months and 3 months, respectively, at 10,000-cell injection. Moreover, when we treated the
DTCs with a DNA methyltransferase inhibitor, Aza, the tumorigenicity of Du145-VP16
cells can be partially restored, with tumor incidence up to 3/10. In addition, after treatment
with Aza and a histone deacetylase inhibitor, TSA, the reduced CD44 levels in some DTCs
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rebounded in a dose-dependent manner. Furthermore, TSA and Aza treatment in DTCs can
also increase the expression levels of E-cadherin and KDM5A. Reduced E-cadherin levels
have been associated with the invasiveness and metastasis of cancer cells (159), which can
be attributed to DNA methylation (160, 161) and histone deacetylation (162). Our data
supports the idea that epigenetic regulation is important in suppressing E-cadherin
expression. Of particular interest, a recent report has shown that KDM5A, a histone
demethylase, plays a vital role in directly mediating a drug tolerant phenotype in lung cancer
cells (152). Our DTCs also show enhanced levels of KDM5A: after TSA and Aza treatments,
KDM5A protein levels in Du145-DTCs increase significantly, implying that this histone
demethylase itself may be regulated by novel epigenetic mechanisms yet to be uncovered.
Whether KDM5A-mediated drug tolerance in lung cancer cells is also involved in the
reduced levels of CD44 in PCa DTCs will be an interesting subject to explore.
In this study, we have shown that the clinically used chemotherapy drugs, VP16 and
Taxol, can significantly ablate CD44+ Du145 PCa cells, which are known to be enriched in
CSCs. However, why do these drugs fail to cure PCa patients by wiping out CSCs? One
possibility is that delivery of these drugs is not efficient enough to effectively reach and
target CD44+ CSCs in the prostate tumors. The second possibility is that because CSCs are
heterogeneous (7), even if these commonly used chemotherapy drugs are capable of
eliminating CD44+ CSCs, other CSC populations may be spared, which may drive tumor
relapse and metastasis. Finally, it is also possible that CD44+ PCa cells may represent a
population of intermediate cycling cells (85) that can be targeted by chemotherapeutic drugs.
However, more quiescient tumor cells still exist after clinical treatments, which may be
therapy-resistant and sustain tumor propagation. It is crucial that a long-term study should
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be conducted to clarify what is occurring in these instances. Therefore, identifying the longterm slow cycling/quiescent PCSCs will be significant not only for our understanding of the
disease, but also for possible future therapy development.
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2.5. Future Studies
For this project, one of the most interesting questions to be addressed in the future is
to understand how CD44+ Du145 cells are ablated by the chronic drug exposure. One
potential mechanism relates to epigenetic regulation by molecules such as KDM5A. In
Du145-VP16 cells, CD44 protein levels decrease accompanied by increased KDM5A,
suggesting that KDM5A, as a histone lysine demethylase, might directly target CD44 gene
and regulate its expression. To test this suggestion and to determine the relationship between
the two molecules, we will first use qPCR to examine the basal expression levels of
KDM5A and CD44 using Du145 and Du145-DTCs (e.g., Du145-VP16). The purpose is to
determine whether the reciprocal changes in the two molecules take place at the
transcriptional level. Then, KDM5A will be knocked down in Du145-DTCs, followed by
examination of the expression levels of CD44 at both mRNA and protein levels. If KDM5A
is causally involved in shutting down CD44, its knockdown is predicted to boost CD44
mRNA and protein levels. Tumor-initiating experiments using LDA and in vitro
proliferation (i.e., Ki67 or BrdU incorporation assays) and sphere-formation experiments
will be used to determine the effects of KDM5A knockdown, which we expect should
‘phenocopy’ CD44 overexpression in these cells. Subsequently, in a reciprocal experiment to
further confirm the gene knockdown results, a lentiviral-mediated gene overexpression of
KDM5A will be conducted in Du145 cells, followed by characterization of CD44 expression
and tumor-initiating and clonogenic capacities. Finally, to test whether KDM5A is directly
involved in epigenetic regulation of CD44 transcription, a chromatin immunoprecipitation
(ChIP) assay will be performed to examine the recruitment of KDM5A to the endogenous
promoter region of CD44. We expect to see that KDM5A will bind to the promoter region of
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CD44 and regulate CD44 expression by inhibiting its transcription. Collectively, the aboveproposed experiments will allow us to obtain a better understanding of the epigenetic
mechanisms regulating CD44 expression in our drug-tolerant PCa cells.
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Chapter 3

Dissociated Primary Human Prostate Cancer Cells Coinjected with the
Immortalized Hs5 Bone Marrow Stromal Cells Generate Undifferentiated
Tumors in NOD/SCID-IL2Rγ-/- Mice
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3.1. Introduction
As introduced earlier in Chapter 1, the majority of studies on PCSCs have used longterm cultured PCa cells or xenograft tumors (7). A KEY unanswered question is whether
similar stem-like PCa cells with enhanced tumor-propagating properties also exist in
primary human PCa (HPCa) samples. The reason that this important question has dodged a
definitive answer lies in the fact that we have yet to establish a RELIABLE assay system
that can REPRODUCIBLY and FAITHFULLY reconstitute tumor regeneration from single
HPCa cells (83). Most currently used PCa models are derived from either genetically
modified mice where specific genes are overexpressed or knocked out or from xenografts by
using human cancer cell lines or tumor pieces inoculated orthotopically or ectopically into
the immunodeficient mice (2). For many reasons, mouse models of PCa possess
histopathological characteristics that are not entirely representative of human PCa, which are
often characterized by multiple genetic alterations that are beyond the ability of any
genetically engineered models may recapitulate. Moreover, a specific genetic mutation may
result in distinct biological and histological phenotypes in animals versus in human (163). In
contrast, xenograft models are widely studied for the ease of use. They are of human origins
and therefore are believed to better recapitulate human tumors in terms of the
histopathological and molecular characteristics (2).
Several widely used PCa xenografts, such as the LAPC and LuCaP series (164-166),
have been established by implanting human prostate tumor pieces in immunodeficient mice.
PCa xenografts can also be created by injecting established PCa cell lines such as PC-3
(bone metastasis), Du145 (brain metastasis), and LNCaP (lymph nodes metastasis) (131).
Due to the well-known fact that localized PCa or PCa cells rarely form tumors in
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immunodeficient mice (131), the above-mentioned examples of xenografts or cell lines were
all established from metastases, and they only represent a minority of surgically removed
human PCa and do not completely reflect the heterogeneity of the disease. Recently, efforts
have been made to generate PCa xenografts by grafting localized PCa pieces (167, 168) or
primary PCa cells recombined with neonatal mouse mesenchyme (169) in the renal capsule.
The regenerated xenografts appear to resemble, histopathologically, the donor patient
tumors, but whether they could be serially passaged is unknown.
The main goal of our current project is to establish a reliable assay system that would
allow us to reproducibly and faithfully reconstitute human prostate tumor regeneration in
mice using patient tumor-derived HPCa single cells. We have previously made some efforts
towards this goal but most of our reconstitution protocols completely failed to regenerate
tumors (83). Here, we have utilized many of the 114 untreated prostatectomy samples,
ranging from Gleason Score (GS) 6 to 10, to prepare single epithelial cancer cells, which
were recombined with different stromal cells including rUGM, carcinoma-associated
fibroblasts (CAFs), or immortalized bone marrow-derived stromal cells (Hs5), and
implanted at different anatomical sites in either NOD/SCID or NOD/SCID-IL2Rγ-/- (NSG)
mice. Below we present the results of our comprehensive studies.
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3.2. Materials and Methods

Cells, reagents, and animals
PC3, DU145, LNCaP, and Swiss 3T3 cells were obtained from ATCC. Hs5 cells
were kindly provided by Dr. M. Andreeff (M.D Anderson Cancer Center). Carcinoma
associated fibroblasts (CAFs) were prepared as previously reported (170). All cells were
cultured in recommended media containing 7% heat-inactivated FBS, 100 µg/ml
streptomycin, and 200 U/ml penicillin (Gibco). Testosterone was purchased from Sigma.
The TRPC xenograft line was provided by Dr. Palapattu (171). Immunodeficient mice
(NOD/SCID, NSG, Rag2; (83)) were initially purchased from the Jackson Laboratories (Bar
Harbor, ME) and the breeding colonies were established in our animal facility and
maintained in standard conditions according to the institutional guidelines. Antibodies used
in this study are presented in Table 3-1.

Histological and immunohistochemical (IHC) analyses
Tumor tissues harvested from patient tumors and reconstituted xenografts were fixed
in formalin for 24 h followed by 70% ethanol and embedding in paraffin. Sections (4 µm)
were cut and stained with hematoxylin and eosin (HE). For IHC, sections were
deparaffinized and hydrated and endogenous peroxidase activity was blocked with 3% H2O2
in water for 10 min. Antigen retrieval was performed with 10 mM citrate buffer (pH 6.0) for
10 min in a microwave oven followed by a 20-min cool down and thorough wash. Slides
were incubated with Biocare Blocking Reagent (#BS966M with casein in the buffer) for 10
min to block non-specific binding. Slides were incubated with various primary antibodies
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for 30 min at room temperature, and washed in phosphate buffer twice and then incubated in
biotinylated goat-anti-rabbit or mouse IgG (Vector Laboratories, Burlingame, CA) at a
1:500 dilution for 30 min at room temperature. After thorough washing, they were incubated
with SA-HRP (BioGenex, San Ramon, CA) for 30 min at room temperature followed by
washing. Finally, these slides were incubated with BioGenex DAB substrate (color
development closely monitored under a microscope) and lightly counterstained with
hematoxylin. Images were captured using a MagnaFire Camera, and the whole mount slides
were scanned using an Aperio ImageScope system.

Aperio-assisted morphometric analysis
HE or IHC stained glass slides containing patient or xenograft tumors were scanned
by using the Aperio Scanscope imaging platform (Aperio Technologies, Vista, CA, USA)
with a 20× objective at a spatial sampling period of 0.47 µm per pixel. Whole slides images
were viewed and analyzed by using desktop personal computers equipped with the free
ScanScope software.

Purification of tumor cells from primary patient samples and xenograft tumors
Basic procedures have recently been described in Chapter 2. Primary PCa samples
were obtained at radical prostatectomy with patients’ consent according to the MDACC
Institutional Review Board guidelines (IRB LAB04-0498). None of the patients received
any treatment prior to surgery. For patient samples, tumor tissues freshly obtained from
prostatectomy were minced into ~1 mm3 pieces and tissues are subjected to enzymatic
digestion (type I collagenase plus DNase at 50 U/ml) for 8-10 h at 37ºC. Upon digestion,
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epithelial organoids are enriched by a brief centrifugation followed by trypsin digestion
(0.05%, Gibco) on a rocker at 37ºC for 15-30 min to release epithelial cells. For xenografts,
tumor tissues were incubated with 1x Accumax (1200–2000 U/ml proteolytic activity
containing collagenase and DNase; Innovative Cell Technologies, Inc) at 10 ml per gram
tissue for 30 min at room temperature under rotating conditions. Single-cell suspension was
obtained by filtering the supernatant through a pre-wetted 40-µm cell strainer and cell
suspension was then gently loaded onto a layer of Histopaque-1077 (Sigma) gradient
purification step to remove the majority of red blood cells, dead cells and debris. Finally, the
resultant cell mixture was subjected to a MACS lineage cell depletion kit (Miltenyi Biotec)
and the cocktail (anti-CD3, 14, 16, 19, 20, 45, 56, and 140b for patient tumors; H2Kd for
xenografts) to remove the Lin+ cells including hematopoietic, endothelial, and other stromal
cells (smooth muscle, myoepithelial, fibroblast, etc) for patient samples, or mouse stromal
cells for xenograft tumors, respectively.

Tumor transplantation experiments
Purified PCa cells (above), either alone or in combination with helper cells including
rUGM, CAFs, or Hs5 cells, are implanted either subcutaneously (s.c) or under the kidney
capsule (KC) of immunodeficient mice. Alternatively, pieces or fragments of HPCa were
grafted subcutaneously, under the KC, or in the mouse anterior prostate (AP). Basic
procedures for these transplantations have been previously described (83). Briefly, for s.c
implantations, tumor cells were injected, in 40 µl of medium containing 50% Matrigel,
subcutaneously into 6-8 week old male mice supplemented with exogenous testosterone
pellets. For KC transplantations, PCa cells were mixed with 250,000 rUGM cells and tissue
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recombinants were made in rat-tail collagen and incubated overnight. The tissue
recombinants were transplanted next morning under the renal capsule of recipient male mice
supplemented with testosterone pellets. For AP grafting, small pieces of HPCa tissues were
directly implanted. In some cases, HPCa cells at different numbers were first mixed with rat
collagen and incubated in a tissue culture plate at 37° for 10-15 min. Then the solidified cell
pellets were gently covered in medium and cultured for 4 h to overnight prior to
implantation. A transverse incision was made in the lower abdomen to expose the AP by
partially pulling the bladder, seminal vesicles and prostate out of the abdominal cavity. A 23 mm incision was made in the AP through the tubule between the two main ducts with the
aid of a 22-gauge needle. Using a fire-rounded glass pipette tip, the collagen dots were
inserted into a pocket formed under the prostate tubule. Then the organs were replaced and
the body wall and skin closed.
In all above experiments, tumor development was monitored starting from the
second week. Tumorigenicity was measured mainly by tumor incidence (i.e., the number of
tumors/number of injections), latency (i.e., time from injection to detection of palpable
tumors), tumor volume, and endpoint tumor weight.

Fluorescence-Activated Cell Sorting (FACS) and purification of EpCAM+ cells
HPCa/Hs5 tumors cells were treated with FcR blocking agent (Miltenyi Biotec) for
10-15 min at 4°C and stained with PerCP-eFluor 710 conjugated anti-EpCAM antibody and
biotinylated mouse H-2K[d] antibody for 30 min at 4°C. Cells were then washed with PBS
and labeled with Alexa Fluor 405 conjugated streptavidin (Invitrogen, S-32351) for 10 min
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at 4°C. EpCAM+ and EpCAM- cells were further purified using FACS (96, 98). Postanalysis revealed purities of both populations being >98%.

Sphere-Formation Assays
Basic procedures for sphere-formation assays were previously described (96, 98).
We purified EpCAM+ HPCa/Hs5 cells via MACS, and cultured them up in serum-free
prostate epithelial basal medium (PrEBM) containing B27 (Invitrogen), 20 ng/ml EGF and
bFGF in Purecol (Advanced BioMatrix, #5005-B) coated T-25 flasks. When these cells were
confluent, we harvested the cells via 0.05% trypsin/EDTA, and plated the single cells in 6well ULA plates at the density of 5,000–10,000 cells/well. Spheres were scored in ~2 weeks.
For serial sphere-formation assays, the first-generation spheres were harvested with 0.025%
trypsin/EDTA, triturated with a 27-G needle, filtered through a 40-µm strainer, and replated
as above. This process was repeated for up to 3-4 generations.

Western blotting
Whole cell lysates were prepared in complete RIPA buffer (50 mM Tris-HCl, pH
7.5, 150 mM NaCl, 1% Nonidet P-40, 0.5% sodium deoxycholate, 0.5% Triton X-100, 10
mM EDTA) containing protease inhibitor mixture. Protein concentrations were determined
by MicroBCA kit (Pierce). Various amounts of proteins were loaded on a 15% SDS-PAGE.
Western blotting was performed as standard using ECL Plus (PerkinElmer).

Reverse transcription (RT)-PCR analysis
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Total RNA was extracted from tumor pieces or cultured cancer cells using Trizol
(Invitrogen), and used in RT-PCR analysis. The PCR primers included human AR (sense:
5’-GCTAAAGACTCGGAGGAAGCAAG-3’; antisense: 5’-TGGGGGAAAACAGAGGGT
TC-3’); PSA (sense: 5’-TGGGAGTGCGAGAAGCATTC-3’; antisense: 5’-GCTGTGGCT
GACCTGAAATACC-3’);

β-actin

(sense:5’-CTGGCACCACACCTTCTACAATG-3’;

antisense: 5’- AATGTCACGCACGATTTCCCGC-3’).

Karyotyping and genomic instability
Cells were exposed to Colcemid (0.04 µg/ml) for 25 min at 37°C and then to a
hypotonic solution (0.075 M KCl) for 20 min at room temperature. Cells were fixed in a
methanol and acetic acid (3:1 by volume) mixture for 15 min, and washed three times in the
fixative. The slides were air-dried, optimally aged, and G-banded using trypsin solution and
stained in Giemsa following the routine procedure. Images were captured using a Nikon 80i
microscope equipped with karyotyping software from Applied Spectral Imaging (ASI) Inc.,
Vista, CA. and a minimum of 15 G-banded metaphases were karyotyped.

Statistic analysis
Limiting dilution analyzes were carried out using ELDA (http://bioinf.wehi.edu.au/
software/elda/). Tumor-initiating cell frequencies were compared using likelihood ratio tests.
Differences in tumor-take rate were determined by the Proportion test. Statistical
significance was defined as P < 0.05.
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Table 3-1. Primary antibodies used in Chapter 3.
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3.3. Results

HPCa piece xenotransplants show higher tumor takes at subcutaneous site than at
other sites
Our lab has so far worked on 114 patient samples freshly obtained from prostatectomy.
Some of these samples have been used in our previous studies (83, 96, 98) and most of them
were used in the current project. Of the 114 HPCa samples, 15.8% had combined Gleason
Score (GS) 6, 52.6% GS7, 11.4% GS8, and 20.2% GS9. In general, the HPCa samples were
used in 2 types of experiment: either transplanted, as small pieces, in male immunodeficient
mice to generate xenografts or used to make single-cell suspension for in vitro and in vivo
studies (Figure 3-1).
For xenograft studies, we implanted tumor pieces (~2-3 mm3) at three different
anatomical sites (83), i.e., subcutis (s.c), kidney capsule (KC), or anterior prostate (AP) in
one of the three immunodeficient mouse strains, i.e., NOD/SCID, Rag2-/-, or NSG mice.
NOD/SCID mice lack both T and B cells and have functional deficit (though not complete
deficiency) in NK cells and Rag2-/- mice also lack T and B cells whereas the NSG mice are
the most immunodeficient lacking T, B, and NK cells (83, 122). As summarized in Table 32, in every strain of mice and with every grade of HPCa, the s.c implants showed the highest
tumor take compared to KC and AP xenotransplants. Furthermore, in NOD/SCID mice,
which were used most often, we observed increasing tumor takes with increasing tumor
grade at s.c and KC sites (Table 3-2). Interestingly, the tumor grade-associated increase in
tumor takes was not observed in Rag2 and NSG mice and HPCa samples xenotransplanted
in NSG mice did not exhibit an increase in tumor takes compared to those implanted in
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NOD/SCID mice (Table 3-2).

Figure 3-1. Experimental scheme in using HPCa samples.
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Table 3-2. HPCa xenotransplantation using tumor pieces in immunodeficient mice.
a
HPCa pieces (~2-3 mm3) were implanted in the indicated strains of male immunodeficient
mice supplemented with testosterone pellets. For s.c experiments, tumor pieces soaked in
50% Matrigel were surgically implanted. For KC experiments, tumor pieces were directly
implanted in the kidney capsule of the host. For AP implantation experiments, tumor pieces
were surgically grafted in the AP tubules. “-“, not done.bAverage time in days from the start
of tumor piece implantation to the day of harvest. cTumor take refers to the number of
tumors observed/number of implants. N/S: NOD/SCID mice. #P = 0.0003; ¶P = 0.023; @P =
0.13; $P = 0.006; &P = 3.719e-06; *P = 1.464e-06; §P = 0.01 (all conducted by Proportion
test).
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HPCa cells, unlike HPCa pieces, failed to re-initiate tumors in NOD/SCID mice: No
significant effects with rUGM, CAFs, and immortalized human (bone marrow) stromal
(Hs5) cells
Subsequently, we asked whether freshly isolated HPCa cells, rather than tumor
pieces, could also regenerate tumors in any of the immunodeficient mice. In the very
beginning, we recombined HPCa cells with rUGM for KC transplantations or mixed the
HPCa cells in 50% Matrigel for s.c injections in male NOD/SCID mice (83). In 3 GS6
HPCa (HPCa9, 10, and 16) samples, when 10,000 to 100,000 HPCa cells recombined with
rUGM were implanted under the KC, we observed 0/30 outgrowth (83). Similarly, in 2 GS7
HPCa (HPCa11 and 14) samples, when 10,000 to 200,000 HPCa cells recombined with
rUGM were implanted under the KC, we observed 0/17 outgrowth (83). Finally, when 1
million of HPCa18 (GS7) cells were injected s.c in 50% Matrigel, there was no single tumor
out of 4 injections (83). We then purified CD44+, CD133+ or CD44+CD133+ (and
corresponding marker-negative) HPCa cells from 4 GS6 tumors (HPCa 9, 10, 13, and 16), 4
GS7 tumors (HPCa4, 6, 8, and 12), and 1 GS9 tumor (HPCa42) and implanted increasing
numbers of cells (from 1,000 to 2 million) subcutaneously (for the GS9 HPCa cells) or in the
KC or AP (for the rest) of the male NOD/SCID mice and we observed 0/225 outgrowths
(83). We also purified CD44+/CD44- HPCa cells from 3 GS8 (HPCa25, 32, and 33) and 1
GS9 (HPCa24) primary (1º) xenografts and implanted 1,000 to 500,000 cells in 50%
Matrigel at the most sensitive site, i.e., subcutis of male NOD/SCID mice. Again, we did not
observe any tumor regeneration out of 52 implantations (83). Finally, when unsorted HPCa
cells purified from 3 GS6 tumors (HPCa2, 10, and 16), 4 GS7 tumors (HPCa3, 11, 14, and
18), 2 GS8 tumors (HPCa15 and 37), and 2 GS9 (HPCa5 and 21), either injected alone in
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Matrigel s.c or recombined with rUGM and then transplanted under the KC, gave rise to
0/92 tumors (83). In all these transplantation experiments, the male NOD/SCID mice were
supplemented with exogenous testosterone pellets.
Next, we co-injected unsorted or marker-sorted HPCa cells with carcinomaassociated fibroblasts (CAFs), which have been reported to promote tumor development in
some experimental systems (172), either subcutaneously or under the KC of testosteronesupplemented male NOD/SCID mice. We observed 3 outgrowths out of total 56 injections
(Table 3-3). Nevertheless, the 3 outgrowths were not serially transplantable (Table 3-3).
Recently, human bone marrow derived mesenchymal stromal (or stem) cells (MSCs)
have been shown to integrate into the tumor-associated stroma and promote breast cancer
cell metastasis (173). We wondered whether MSCs might facilitate tumor reconstitution by
primary HPCa cells. The Hs5 cell line, generated from human bone marrow, was
immortalized by transduction with human papilloma virus E6/7 genes (174), and shown to
support proliferation of PCa cells in cultures (175, 176). We thus subcutaneously coinjected
unsorted or marker-sorted (i.e., CD44) HPCa cells (from 2 GS6, 3 GS7, 4 GS8 and 1 GS9)
with 100,000 Hs5 cells into NOD/SCID mice. We observed 4 tumors in a total of 54
injections (Table 3-4). Again, the 4 regenerated tumors could not be serially transplanted
(not shown). Hs5 cells alone did not generate tumors in NOD/SCID mice at ≤ 100,000 cells.
Taken together, our prior (83) and current studies indicate that NOD/SCID mice are
not permissive for reconstituting transplantable tumors from primary HPCa cells, even in the
presence of rUGM, CAFs, or MSCs such as Hs5.
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Table 3-3. Unsorted or marker-sorted HPCa cells mixed with CAFs fail to initiate
transplantable tumors in NOD/SCID mice. For s.c injections, cells were mixed with
100,000 CAFs and implanted subcutaneously in 50% Matrigel; For KC transplantations,
cells were first recombined with 250,000 CAFs and then transplanted under the kidney
capsule. All injections/transplantations were carried out in 6-8 week old male NOD/SCID
mice supplemented with testosterone pellet.
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Table 3-4. Unsorted or marker-sorted HPCa cells mixed with Hs5 cells fail to initiate
transplantable tumors in NOD/SCID mice. Unsorted or purified CD44+/CD44- HPCa
cells were mixed with 100,000 Hs5 cells and injected subcutaneously in 50% Matrigel in 6-8
weeks old male NOD/SCID mice supplemented with testosterone pellet.
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Hs5 cells induce HPCa cells to initiate transplantable tumors in NSG mice
What if we utilize more immunodeficient mice? We first injected freshly purified
primary HPCa cells from 5 patients (2 GS7, 1 GS8, 2 GS9) subcutaneously into NSG mice.
In a total of 37 injections, we did not observe any tumor growth after 8 months (Table 3-5).
Since Hs5 cells slightly increased tumor regeneration of HPCa cells in NOD/SCID mice
(Table 3-4), we therefore hypothesized that subcutaneous coinjection of primary HPCa cells
with Hs5 cells into NSG mice will allow us to reconstitute HPCa in immunodeficient mice
using patient cells.
In 9 patient samples, this modified ‘recombination protocol’ remarkably induced
tumor formation in 41/59 injections (i.e., ~70%; Table 3-6). HPCa cells derived from 3 GS9,
1 GS8, and 4 GS7 tumors all regenerated tumors when coinjected with Hs5 cells (Table 3-6).
We also established 1º xenografts in Rag2 mice from pieces of 3 other HPCa tumors (i.e.,
HPCa57, 58, and 70). When the 1º xenograft cells were purified out and coinjected with Hs5
cells into male Rag2 or NSG mice, we readily obtained the 2º xenografts ((96, 98); data not
shown). In total, we have established 11 HPCa/Hs5 xenografts from 7 GS7 (HPCa57, 58, 70,
83, 84, 85, and 92), 1 GS8 (HPCa91), and 3 GS9 (HPCa80, 87, and 96) tumors. These
results seem to suggest that Hs5 cells highly efficiently promote tumor regeneration from
fresh HPCa cells in NSG mice.
The reconstituted tumors were highly tumorigenic and could be passaged indefinitely
(Table 3-7; data not shown). Also, the regenerated tumors were able to give rise to
transplantable tumors independently of Hs5 cells (Table 3-7). Moreover, unsorted or CD44sorted (both CD44+ and CD44-) HPCa cells were able to re-initiate tumors both
subcutaneously and in the dorsal prostate (DP) and, significantly, HPCa cells purified from
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the xenografts initially established in NSG mice could regenerate tumors in NOD/SCID
mice (Table 3-7; data not shown).

Reconstituted “prostate” tumors are of human origin and present an undifferentiated
and epithelial morphology: IHC, biochemical, and molecular characterizations
We first carried out histological and IHC analyses of the reconstituted tumors. As
expected, the HPCa57 patient tumor exhibited typical GS7 histology with crowded tumor
glands, in which most cells stained positive for luminal prostate epithelial cell markers PSA,
nuclear AR, and cytokeratin 8 (CK8) (Figure 3-2A). Also, tumor glands showed positive
staining for racemase (alpha-methylacyl-CoA racemase, also known as AMACR or P504S;
encoded by the AMACR gene), negative (or weakly positive) staining for CK5 (a prostate
basal epithelial marker), and negative for p63 (another basal cell marker) (Figure 3-2A). The
HPCa57/Hs5 reconstituted tumors in NSG mice appeared completely undifferentiated and
lacked glandular structures and PSA expression (Figure 3-2B). The cells looked overall
epithelial, as supported by the presence of some CK8+ and sporadic CK5+ cells (Figure 32B). Interestingly, scattered AR+ and p63+ cells could be observed (Figure 3-2B). Staining
with human-specific antibodies against mitochondria and Ki-67, both of which did not stain
mouse tissues (Figure 3-3), confirmed the human origin of the regenerated HPCa57 tumor
(Figure 3-2B). Similar patterns of morphology and marker expression were observed in Hs5reconstituted HPCa58 (Figure 3-4) and 9 other HPCa samples, i.e., HPCa70, 80, 83, 84, 85,
87, 91, 92, 96 (data not shown).
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Table 3-5. Freshly purified and unsorted HPCa cells injected in NSG mice. Freshly
purified and unsorted HPCa cells were subcutaneously injected in 50% Matrigel in 6-8 week
old male NSG mice supplemented with testosterone pellet.
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Table 3-6. HPCa cells mixed with Hs5 cells initiate serially transplantable tumors in
NSG mice. Freshly purified and unsorted HPCa cells at the indicated numbers were
recombined with 100,000 Hs5 cells and then subcutaneously injected in 50% Matrigel in 6-8
week old male NSG mice supplemented with testosterone pellet.
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Table 3-7. Reconstituted ‘prostate’ tumors are independent of Hs5 cells, host, and
injection site. Bulk or CD44+/CD44- HPCa cells were purified from primary (1º) xenografts
and used in subsequent (2º, 3º, etc) xenotransplantations (either s.c or DP) in the presence or
absence (-) of 100,000 Hs5 cells in male NOD/SCID (NS) or NSG mice supplemented with
testosterone pellet.
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Consistent with the IHC results, RT-PCR analysis using human-specific primers
revealed that none of the HPCa/Hs5 xenografts expressed PSA but most expressed different
levels of AR mRNA (Figure 3-5). Notably, cultured murine fibroblasts (Swiss 3T3) and Hs5
cells were negative for both AR and PSA mRNAs (Figure 3-5). Western blotting
experiments for 4 luminal cell markers, racemase, PSA, AR, and CK18 confirmed lack of
PSA expression and revealed varying levels of the other 3 markers in different xenografts
(Figure 3-6). Note that cultured Hs5 cells and Hs5 tumors (see below) did not express CK18
(Figure 3-6C, arrow) although they expressed low levels of racemase (Figure 3-6).
Occasionally, Hs5 tumors were found to express low levels of AR protein (Figure 3-6B)
although they expressed barely detectable AR mRNA (Figure 3-5). Most HPCa/Hs5
xenografts expressed higher levels of racemase than PC3 cells (Figure 3-6A). Interestingly,
western blotting for p63 revealed very high levels in PC3 and LNCaP cells, readily
detectable expression in HPCa57 and HPCa96 xenografts, and very low levels in several
other HPCa xenografts (HPCa58,70, and 91) (Figure 3-6A). These results overall suggest
that the HPCa/Hs5 xenografts contain human prostatic epithelial cells. As further support,
western blotting of AR and CK18 on a series of HPCa57/Hs5 xenograft tumors, from the 1º
generation (P1) to the 4º generation (P4), derived from s.c or DP implantations, showed that
all these tumors were positive for AR and CK18 (Figure 3-6D).
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Figure 3-2. IHC analysis of HPCa57 patient sample (GS7) and its xenograft tumor. (A)
Staining of HE, AR, PSA, CK8, CK5, p63 and Racamase in HPCa57 patient sample. (B)
HPCa57P1 xenograft tumor, derived from coinjection with 100,000 Hs5 cells, was used to
make serial sections, which were stained for HE, Hu-mito, Hu-ki67, AR, PSA, CK8, CK5
and p63. Both low (i.e., 100x) and high-power (i.e., 400x) magnifications were shown. The
arrow indicates a CK5+ cells.
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Figure 3-3. Testing antibody specificity in mouse prostate tumors. Serial sections from
the Hi-Myc mouse prostate tumors were stained for HE, Hu-ki67, Hu-mito, or mouse-ki67
antibodies. Both low (i.e., 100x) and high-power (i.e., 400x) magnifications were shown.
Note that although mouse-specific Ki-67 antibody stained positively, the human-specific
anti-Ki67 and anti-mitochondria antibodies did not manifest any specific staining.
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Figure 3-4. IHC analysis of HPCa58 patient sample (GS7) and its xenograft tumor. (A)
Staining of HE, AR, PSA, CK8, CK5, p63 and Racamase in HPCa58 patient sample. (B)
HPCa58P1 xenograft tumor, derived from coinjection with 100,000 Hs5 cells, was used to
make serial sections were stained for HE, Hu-mito, Hu-ki67, AR, PSA, CK8, CK5 and p63.
Both low (i.e., 100x) and high-power (i.e., 400x) magnifications were shown. The arrow
indicates a CK5+ cells.
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Figure 3-5. RT-PCR characterization of HPCa/Hs5 xenograft tumors. RT-PCR results
of AR, PSA, and β-actin using human-specific primers. LNCaP, TRPC (treatment-refractory
prostate cancer; (171)) and Du145 cells were used as controls.
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Figure 3-6. Western blotting characterizations of HPCa/Hs5 xenograft tumors. (A-C)
Western blotting of Racemase, PSA, p63, AR and CK18 on HPCa-Hs5 xenograft tumors
and the tumor cell-derived spheres. GAPDH and β-actin were used as loading controls. The
arrow in C indicated the CK18 protein band (note that Hs5 cells and Hs5 tumor had some
non-specific lower M.W bands). (D) Western blotting of AR, CK18 and β-actin in
HPCa57/Hs5 serial xenograft tumors (P1-P4) from either subcutaneous or orthotopical (DP)
injections. LNCaP and Du145 cells were used as controls.
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Cytogenetic evidence for presence of human PCa cells in HPCa/Hs5 xenograft tumors
and physical contributions of Hs5 cells to the xenografts
Our cytogenetic analyses (Figure 3-7) provided further evidence for the conclusion
that HPCa/Hs5 xenografts contain human prostatic epithelial cells. The cultured Hs5 cells
showed multiple chromosomal abnormalities with at least 5 marker chromosomes, i.e., M1
[del(1p)], M2 [del(2p)], M3 [der(2)], M4 [der(11)], and M5 [13q+] (Figure 3-7A). HPCa70
cells derived from either tumor piece implant (Figure 3-7B) or Hs5 coinjections (Figure 37C) showed similar karyotypic features that were distinct from the cytogenetic makeup of
Hs5 cells. Specifically, tumor cells from both HPCa70/Hs5 coinjections and pieces implant
showed a deletion at chromosome 10, which is a common chromosomal abnormality in PCa
(177-179).
On the other hand, when we performed similar cytogenetic analysis in cells derived
from HPCa57/Hs5 and HPCa87/Hs5 coinjections, most cells we were able to karyotype
showed karyotypic features similar to those of Hs5 cells (not shown), suggesting that
epithelial human PCa cells in these tumors represented the minority with Hs5 cells being the
majority. Also, the overall histological and structural dissimilarities between the HPCa/Hs5
xenografts and the corresponding patient tumors made us wonder whether Hs5 cells might
have physically contributed to the establishment of the xenografts. In partial support of this
conjecture, Hs5 cells injected alone were capable of initiating tumor development in NSG
mice with a grafting efficiency at ~52.5% (Table 3-8). Both Hu-mito and Hu-Ki67 staining
of the Hs5 cell-derived tumors was positive (Figure 3-8, top), confirming their human origin.
The Hs5 tumors manifested a stromal morphology, and IHC staining of these tumors was
completely negative for PSA, CK8, CK5 and p63 (Figure 3-8), consistent with RT-PCR and
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western blotting results (Figure 3-5; Figure 3-6). AR staining was observed in some cells but
only in the cytoplasm (Figure 3-8). These data, taken together, suggest that Hs5 cells were
tumorigenic in the highly immunodeficient NSG mice, but tumors derived from these cells
were distinct from HPCa/Hs5 xenograft tumors.

The reconstituted HPCa/Hs5 tumors contain EpCAM+ epithelial cancer cells that can
regenerate tumors that contain both epithelial and mesenchymal-like cells
To provide further evidence that reconstituted HPCa/Hs5 tumors contain epithelial
cells, we analyzed the expression of epithelial cell adhesion molecule (i.e., EpCAM) and
detected a small percentage of EpCAM+ cells in the HPCa/Hs5 (e.g., ~0.2% in
HPCa58/Hs5) tumors (Figure 3-9A; data not shown). To functionally analyze these
EpCAM+ PCa cells, we purified out EpCAM+ and isogenic EpCAM- cells from
HPCa58/Hs5 tumors and injected them into male NSG mice. Interestingly, the EpCAM+
cells in HPCa58/Hs5 tumors were capable of regenerating tumors with as few as 100 cells,
and, importantly, the EpCAM+ cell-derived tumors comprised both epithelial- and stromallike cells (Figure 3-9B). In contrast, EpCAM- cells gave rise to tumors consisting of only
stromal-like cells (Figure 3-9B).
We also sorted out EpCAM+ cells from HPCa58/Hs5 tumors via Magnetic Activated
Cell Sorting (MACS), cultured them in PrEBM medium in collagen treated plates, and,
finally, tested their sphere-forming capacities (Figure 3-9C). We observed that most
EpCAM+ cells attached and proliferated to give rise to cells that were capable of generating
serially passageable spheres in the ultra-low attachment plates (Figure 3-9D). Importantly,
these spheres were positive for CK18 (Figure 3-6C). Taken together, these results further
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indicate that the reconstituted HPCa/Hs5 tumors contain a subset of epithelial (EpCAM+)
PCa cells that are clonogenic as well as tumorigenic.
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Figure 3-7. Cytogenetic analysis of HPCa/Hs5 xenograft tumors. (A) An example of Hs5
cell karyotype. (B-C) Karyotypes of xenograft cells derived from HPCa70 piece
implantation (B) or from HPCa70/Hs5 coinjections (C).
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Figure 3-8. Histological analysis of Hs5 tumors. Serial sections were stained for HE, Humito, Hu-ki67, AR, PSA, CK8, CK5 and p63. Both low (i.e., 100x) and high-power (i.e.,
400x) magnifications were shown.
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Table 3-8. Cultured Hs5 cells initiate tumor development in NSG mice. Hs5 cells were
subcutaneously injected in 50% Matrigel into 6-8 week old NSG mice supplemented with
testosterone pellet.
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Figure 3-9. Functional characterizations of EpCAM+ cells in HPCa/Hs5 tumors. (A)
FACS analysis of EpCAM expression in cultured Hs5 cells and tumor cells harvested from
HPCa58P/Hs5 tumors (P5). (B) HE staining of tumors derived from 100 EpCAM+ and
EpCAM- cells from HPCa58/Hs5 tumors. (C) Scheme of sphere formation assays using
HPCa/Hs5 xenograft tumor cells. (D) Representative images of spheres derived from
EpCAM+ HPCa84 and HPCa87 tumor cells (100x).
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Evidence that undifferentiated HPCa cells might be the cells that reconstituted the
HPCa/Hs5 tumors
The observations that GS7 tumors such as HPCa57 and HPCa58, which contained
well-differentiated glandular structures, nevertheless reconstituted tumors as fully
undifferentiated tumors (Figure 3-2; Figure 3-4) are rather intriguing. When the wholemount sections were analyzed under Aperio ScanScope, we observed discernible regions of
poorly differentiated or undifferentiated tumor cells in all GS7 tumors such as HPCa57
(Figure 3-10), HPCa58 (Figure 3-11), and HPCa70 (Figure 3-12). On the other hand,
although most tumor cells in GS9/10 tumors were poorly differentiated or undifferentiated,
differentiated areas with glandular structures could clearly be observed (e.g., HPCa101;
Figure 3-13). These cellular and structural heterogeneities in patient prostate tumors raised a
possibility that undifferentiated HPCa cells might be the cells that survived in the tumor
microenvironment and gave rise to transplantable xenograft tumors in the presence of Hs5
cells.
As indirect support for this possibility, we have successfully established two “pure”
HPCa xenograft lines, i.e., HPCa70 and HPCa101 that were derived from primary tumor
pieces implanted subcutaneously into the NSG mice. In HPCa70 patient tumor, most tumor
cells were highly positive for luminal markers AR, PSA, CK8, and racemase but weakly
positive for CK5 and negative for p63 (Figure 3-14A). Strikingly, the HPCa70 xenograft
tumor, which was established by implanting tumor pieces without Hs5 cells presented a
fully undifferentiated morphology and IHC staining was negative for PSA and weakly
positive for AR (Figure 3-14B). The tumor piece-derived xenograft tumors were expectedly
of the human origin (Hu-ki67+, Hu-mito+) and contained CK8+ and CK5+ cells (Fig. 3-14B).
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Similarly, in the HPCa101 patient tumor (GS9), most tumor cells were positive for nuclear
AR but moderately positive for CK8 and PSA, perhaps due to their overall poorly
differentiated nature (Figure 3-15A). As expected, the corresponding HPCa101 xenograft
tumor derived from pieces implant showed an undifferentiated morphology, was negative
for PSA and p63 and weakly positive for AR, and contained CK8+ and CK5+ epithelial cells
(Figure 3-15B). These striking observations in two tumor pieces-derived xenograft tumors,
which histologically and immunophenotypically resembled the HPCa/Hs5 reconstituted
xenograft tumors, raised the possibility that undifferentiated HPCa cells might have a
survival advantage to regenerate tumors.
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Figure 3-10. Histological and cellular heterogeneity in HPCa57 (GS7) prostate tumors.
Shown are whole-mount Aperio Scanscope images of HPCa57 patient tumors, in which
benign (B) glands, differentiated (D), and undifferentiated (U) tumor areas can be identified.
Enlarged images of one differentiated and two undifferentiated areas are shown on the right.
The magnifications of the original objectives are indicated.
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Figure 3-11. Histological and cellular heterogeneity in HPCa58 (GS7) prostate tumors.
Shown are whole-mount Aperio Scanscope images of HPCa58 patient tumors, in which
benign (B) glands, differentiated (D), and undifferentiated (U) tumor areas can be identified.
Enlarged images of one differentiated and two undifferentiated areas are shown on the right.
The magnifications of the original objectives are indicated.
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Figure 3-12. Histological and cellular heterogeneity in HPCa70 (GS7) prostate tumors.
Shown are whole-mount Aperio Scanscope images of HPCa70 patient tumors, in which
benign (B) glands, differentiated (D), and undifferentiated (U) tumor areas can be identified.
Enlarged images of one differentiated and two undifferentiated areas are shown on the right.
The magnifications of the original objectives are indicated.
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Figure 3-13. Histological and cellular heterogeneity in HPCa101 (GS9) prostate
tumors. Shown are whole-mount Aperio Scanscope images of HPCa101 patient tumors, in
which benign (B) glands, differentiated (D), and undifferentiated (U) tumor areas can be
identified. Enlarged images of one differentiated and two undifferentiated areas are shown
on the right. The magnifications of the original objectives are indicated.
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Figure 3-14. Histological analysis of HPCa70 (GS7) patient sample and its piece
implant-derived xenograft tumor. (A) Staining of HE, AR, PSA, CK8, CK5, p63 and
Racamase in HPCa70 patient sample. (B) HPCa70 xenograft tumor, derived from primary
HPCa70 tumor pieces implantation, was used to make serial sections, which were stained for
HE, Hu-mito, Hu-ki67, AR, PSA, CK8, CK5 and p63. Both low (i.e., 100x) and high-power
(i.e., 400x) magnifications were shown.
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Figure 3-15. Histological analysis of HPCa101 (GS9) patient sample and its piece
implant-derived xenograft tumor. (A) Staining of HE, AR, PSA, CK8, CK5, p63 and
Racamase in HPCa101 patient sample. (B) HPCa101 xenograft tumor, derived from primary
HPCa101 tumor pieces implantation, was used to make serial sections, which were stained
for HE, Hu-mito, Hu-ki67, AR, PSA, CK8, CK5 and p63. Both low (i.e., 100x) and highpower (i.e., 400x) magnifications were shown.
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3.4. Discussion
The PCa field has long been hampered by the paucity of suitable xenograft models.
There are two lines of studies that attempt to reconstitute human PCa development in
immunodeficient mice, i.e., tumor piece implantation and cell injection. In the past, PCa
xeonografts from either way were mainly derived from metastasis (164-166). It is
conceivable that more challenges exist to establish xenografts using single cells derived
from primary human PCa samples in that many factors will contribute to the complexity of
reconstitution such as Gleason score, tumor type, relative abundance of tumor cells, host,
applied methodologies, etc (83). As a result, tumor piece implantation has been used more
widely. It is believed that such “tumorgrafts” should recapitulate primary patient tumors
histopathologically and molecularly (180), at least to a certain degree.
Various groups have attempted to establish HPCa xenograft models by using tumor
piece implantation. For example, Wang and colleagues compared the efficiency and
histopathologic patterns of xenografting both benign and malignant human prostate tissue
(low- to mid-grade) into different sites (subrenal, orthotopic and subcutaneous) of SCID
mice, and they showed that both subrenal capsule and orthotopic sites could be used for
HPCa xenograft studies with respect to high take rate and histopathologic differentiation
(181). More recently, Priolo and colleagues implanted 30 primary localized prostate tumor
pieces into the KC site of Nu/Nu or NOD/SCID mice, and they obtained a 56% tumor take
with very low tumor take from subcutaneous and orthotopic implantations (167). The
xenografts from subrenal site maintained both grading and expression of phenotypic markers
of the parental patient tumors (167). Also, a tissue slice graft model has been developed by
subrenal implantation of fresh thin, precision-cut tissue slices derived from 2 primary patient
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adenocarcinomas into RAG2-γ mice, and this model has been advocated as a tool to model
all stages of PCa (168). Most of these implantations have been done in the subrenal site, in
which tumor growth is somewhat limited. Also, whether these grafted tumors can be serially
transplanted remains unknown. In our study, we implanted primary tumor pieces from 78
untreated patients (ranging from GS6-GS9) into the male NOD/SCID, Rag2, or NSG mice
supplemented with testosterone at 3 different sites (i.e., SC, KC and/or AP) (Table 3-2). Our
results reveal the subcutaneous site to be the most sensitive in NOD/SCID mice in allowing
tumor piece grafting. In addition, tumor grade positively correlates with tumor take at the
subcutaneous site. Importantly, we have established two serially transplantable xenograft
models from two primary patient samples using subcutaneous tumor piece implantation, i.e.,
HPCa70 (GS7) and HPCa101 (GS9) (Figure 3-14 and Figure 3-15). To our knowledge,
these two xenograft lines are among the few serially transplantable PCa models that
originate from primary patient tumors.
Reconstitution of PCa in the immunodeficient mice from patient-derived HPCa
single cells is much more challenging, explaining, partially, why there is a limited number of
PCa cell lines currently available (182). This challenge is also the underlying reason why it
has yet to be demonstrated that human PCa cells freshly purified from patient tumors
contain stem-like cancer cells that can initiate serially transplantable tumors, a gold standard
to functionally characterize CSCs in vivo, although such studies have been done with many
PCa xenograft models or cultured cell lines (see Introduction). It is rather striking how
indolent primary PCa cells are compared to many other tumor cells such as melanoma,
colorectal cancer, and glioblastoma cells, which, when freshly purified from patient tumors
and implanted in Matrigel in immunodeficient mice, can readily regenerate xenograft tumors
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that even have defined structures (e.g., glands) (7, 122). In sharp contrast, acutely purified
HPCa cells, either bulk or marker-enriched, are virtually non-tumorigenic when implanted in
Matrigel in NOD/SCID or NSG mice, even in the presence of “helpers” such rUGM and
CAFs ((83); this study).
There are several novel and important findings from our current study. First, bulk or
marker-sorted HPCa cells, when injected alone in 50% Matrigel, cannot induce tumor
growth, even in the highly immunodeficient NSG mice, supporting the notion that HPCa
cells are quite indolent. These results also suggest that either primary HPCa cells need
special microenvironment to maintain their growth in vivo, or they need manipulations to
enhance their tumor-initiating potential. About this latter point, it has been recently shown
that basal cells from primary benign human prostate tissues are capable of initiating PCa in
NSG mice upon overexpressing 3 oncogenic molecules (i.e., AKT, ERG, and AR) (183).
Second, although HPCa cells coinjected with rUGM, CAFs, or Hs5 cells do not
regenerate serially transplantable tumors in NOD/SCID mice after 6-9 months, Hs5 cells
significantly enhance the ability of HPCa cells to initiate serially transplantable tumors in
NSG mice (~10-fold increase compared to in NOD/SCID mice). Thus, our results in PCa
substantiate that more immunodeficient mice dramatically increase primary tumor
take/incidence, as shown in melanoma (122). Furthermore, our study hints that certain
microenvironments (e.g., coinjection of ‘helper’ cells) may likely help primary HPCa cells
set a foothold in vivo. To our knowledge, our work is the first in the field to systematically
compare tumor take/incidence in both NOD/SCID and NSG mice by using patient-derived
HPCa single cells.
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Third, recent evidence suggests that bone marrow-derived human MSCs increase
tumor grafts of human breast cancer cells by promoting angiogenesis (184) as well as
enhance metastatic capacities (173). Here we report, for the first time, that the immortalized
human MSCs (i.e., Hs5) reliably promote human prostate tumor reconstitution in NSG mice.
Several pieces of evidence support the presence of epithelial PCa cells in the reconstituted
HPCa/Hs5 tumors: most tumor cells present an epithelial morphology; CK8+ and CK5+ cells
can be observed; RT-PCR and/or western analyses reveal AR and CK18 expression in most
tumors; karyotyping analysis shows cytogenetic abnormalities characteristic of human PCa
cells; and presence of EpCAM+ cells that are both clonogenic and tumorigenic.
Intriguingly, all HPCa/Hs5 tumors, including those from GS7 tumors, present a fully
undifferentiated histology lacking glandular structures. Consistent with the undifferentiated
tumor histology, all HPCa/Hs5 tumors lack PSA and only express very low levels of AR.
These results suggest that Hs5 cells fail to fully reconstitute the original patient tumor
histology. The fact that prostate tumors are extremely heterogeneous leads us to propose that
it is perhaps only the undifferentiated PCa cells in the primary tumors that have the ability to
reconstitute tumor formation in highly immunodeficient mice. As indirect support for this
proposal, we have recently provided evidence that undifferentiated (i.e., PSA-/lo), compared
to differentiated (PSA+) PCa cells, are enriched in prostate CSCs that possess long-term
tumor-propagating capacity (98). As further support, the phenotype of “undifferentiation” in
our HPCa/Hs5 reconstituted tumors is similar to that in xenograft tumors derived from
HPCa70 and HPCa101 tumor pieces. In fact, it has been reported that subcutaneous
transplantation of primary PCa pieces into nude mice leads to xenograft tumors composed
entirely of undifferentiated cells (185).
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The exact mechanisms by which Hs5 cells support HPCa tumor regeneration need
further investigation. One possibility is that Hs5 cells secrete critical cytokines such as IL-6
that help maintain the survival of undifferentiated PCa cells. Another possibility is that Hs5
cells promote HPCa tumor reconstitution via cell-cell fusion as we have demonstrated that
prostatic epithelial cells and fibroblasts have a high propensity to fuse with each other (186).
It has also been reported that MSCs from FSP1-Cre/Rosa 26 mice were recruited to the
prostate and could fuse with local prostate epithelial cells from β-actin-GFP mice,
manifested by co-expression of β-galactosidase and GFP during prostate regrowth after
castration (187). In addition, the authors found that MSCs were able to home to C4-2B
xenograft tumors and enhance Wnt signaling activity (187). Using a co-culture model, Wang
and colleagues found that some of the cancer-stromal hybrids could survive and led to
colony formation in the co-culture, and these colonies featured with androgen-independent
phenotypes (188). It has been reported that coinjection of tumorigenic rat prostatic
fibroblasts enhanced tumor formation of otherwise non-tumorigenic adjacent prostatic
epithelial cells via paracrine signaling, leading to the formation of carcinosarcoma (189).
The Hs5 cells utilized herein are tumorigenic whereas HPCa cells are non-tumorigenic in
NSG mice, but HPCa/Hs5 coinjections initiate serially transplantable tumors. Importantly,
the HPCa/Hs5 tumors, to a certain degree, resemble carcinosarcomas reported earlier (189).
Cell fusion and carcinosarcoma formation can probably help explain why in general the
EpCAM+ cells in HPCa/Hs5 tumors are rare (i.e., ~0.2% or less). It is interesting that tumors
derived from EpCAM+ cells contain both epithelial and mesenchymal-like cells, suggesting
that EpCAM+ cells might possess some bi-potential differentiation capacity.
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A recent study reported that PCa can be reconstituted from primary HPCa single
cells by coinjecting with neonatal mouse mesenchyme under kidney capsule, which
significantly increased xenografting rate to 32% compared to 0% without the mesenchyme
(169). It remains unclear whether the reconstituted tumors are serially transplantable. More
recently, it has been reported that less differentiated HPCa cells marked by low levels of
HLA expression and injected in Matrigel can initiate serially transplantable tumors in NSG
mice, although the efficiency is rather low, i.e., <10% (105). This study (105) is fully
consistent with ours (98), which, coupled with our current study, strongly suggest that
undifferentiated PCa cells are endowed with the unique capability to regenerate PCa in
immmunodeficient hosts. Future research will focus on better characterizing the
immunophenotypes of undifferentiated PCa cells, which should lead to much improved
tumor reconstitution protocols.
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3.5. Future studies
From our and others’ studies, it is of the utmost importance that we explore and
optimize protocols that may allow us to reliably establish HPCa development in
immunodeficient mice using single patient PCa cells, and that the reconstituted tumor will,
at least partially, restore tumor heterogeneity of the parental tumor. To achieve this, there are
several critical factors that need to be taken into account. We have demonstrated that: 1) the
subcutaneous site is the best site for tumor take of the PCa cells to establish serially
transplantable tumors; 2) using NSG mice undoubtedly increases tumor incidence; 3)
‘helper’ cells will improve PCa survival rate in vivo and boost the likelihood of successful
tumor reconstitution (169); 4) the undifferentiated/poorly differentiated PCa cells may be
THE cells to drive PCa reconstitution in immunodeficient mice. Among these variables, the
most challenging is probably to find ways to select for undifferentiated PCa cells.
There are two potential approaches. First, it has been shown that benign prostate
tissue can be selectively labeled and dissected out from the cancerous tissue in the same
patient prostate tumor, and cells derived from this dissection can be considered as ‘pure’
benign prostatic cells (183). Our lab has been working on primary HPCa for more than 7
years with collaborations from highly experienced surgeons and pathologists (Dr. Fagin R,
Dr. Giesler R, and Dr. Haas J) in TX, and our team is fully capable of performing similar
experiments. To do so, once fresh PCa specimens are obtained, a senior pathology assistant
from St David’s Hospital will prepare several sections of ~4 mm each in thickness. Several
frozen slides will be used to perform HE staining. The undifferentiated/poorly differentiated
regions will be marked and mapped to the rest of the fresh tumor, which will later be
dissociated into single cells as described in the Materials and Methods section. Second, we
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can enrich the undifferentiated PCa cells using the PCSC markers, e.g., PSA-/lo (98) or HLA(105). After the undifferentiated PCa cells have been purified, we will coinject them with
neonatal mouse mesenchyme (169) and inoculate the mixture to different sites in NSG mice,
including s.c, DP, and KC. Tumor growth will be monitored at least twice a week, starting
two weeks after injection. We will record tumor incidence, tumor weight, latency and
weekly tumor volume. After the tissue harvest, the reconstituted tumors will be examined
comprehensively by the following techniques: 1) HE and IHC staining using markers for
PCa cells (e.g., AR, PSA, CK8, CK18, CK5, p63, and Racemase); 2) DNA finger printing to
identify their origin (105); 3) an array-based genome-wide analysis (aCGH) to investigate if
the reconstituted tumors maintains the same genetic background of their parental patient
tumors; 4) Fluorescence in Situ Hybridization (FISH) break-apart assay to test if the PCa
specific genetic abnormality, TMPRESS2-ERG gene fusion, exists in the regenerated tumor
(167). Finally, we expect to see that, with this modified protocol, primary HPCa cells will
re-initiate serially transplantable tumors in immunodeficient mice, providing us with a
reliable in vivo model to study PCSCs in human patient samples.
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Chapter 4

The study on the cell of origin for
castration-resistant prostate cancer (CRPC)
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4.1. Introduction
As mentioned in Chapter 1, many patients who have advanced PCa (GS 9/10) will
initially remain as androgen-dependent PCa (ADPC) and respond well to the ADT,
manifested by tumor regression. However, tumors will eventually recur and develop into
CRPC, which is incurable, metastatic and lethal (also known as AIPC). The etiology of this
process is not clearly understood, but many studies have implicated AR in CRPC
development.

4.1.1. Natural process of androgen action
Both normal and cancerous prostatic cells need androgen to grow and survive.
Testosterone is the most abundant circulating androgen, and it is secreted mainly from the
testis, with a minor portion coming from the adrenal glands (2). Free testosterone circulates
primarily in the blood, and when it enters the prostate, 5α-reductase converts the majority of
free testosterone (>90%) into the more active dihydrotestosterone (DHT), which bears high
affinity for AR binding.
AR, a nuclear hormone receptor, has several domains, including a NH2-terminal
transcription activation domain, a DNA-binding domain, a hinge region, and a carboxyterminal ligand binding domain (46). As shown in Figure 4-1, in the basal level, AR binds to
heat-shock protein (HSP) to prevent its binding to target genes. Once AR binds to androgen,
it will lead to a conformational change in the AR, resulting in the dissociation from HSP and
AR phosphorylation. The phosphorylated AR dimerizes and binds to the androgen-response
elements in the promoter regions of their target genes, forming an AR complex. The AR
complex then recruits co-activators and co-repressors to further mediate AR complex
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interaction with the general transcription apparatus to regulate target gene transcription (190,
191).
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Figure 4-1. Androgen action. Taken from (46) with permission from Nature Publishing
Group.
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4.1.2. Mechanisms of CRPC development
Several mechanisms have been proposed to be responsible for CRPC development
(46). First, AR may become highly sensitive to low levels of androgen via AR amplification,
increased protein stability, or increased levels of circulating androgen. For example, it has
been reported that ~30% of CRPC have an amplified AR gene copy number (192, 193), and
another 10%-30% have mutations of AR resulting in increased AR protein stability and
sensitivity (194). Second, AR mutation is common, and the resultant AR has decreased
sensitivity and can be stimulated by non-androgen hormones and androgen antagonists (46).
For instance, it has been shown that LNCaP cells have a missense mutation of the AR gene,
leading to high levels of AR. Because of this, the androgen antagonist flutamide can activate
AR in LNCaP cells to promote their proliferation (195). Third, like other steroid hormone
receptors, AR can be activated via ligand-independent pathways. For example, a PTEN
deletion in PCa may lead to upregulation of the PI3K/AKT pathway and the phosphorylation
and activation of AR. In addition, growth factors (i.e., IGF-1, EGF and KGF) and receptor
tyrosine kinases (i.e., HER-2/neu) can also activate the AR in different androgen
independent mechanisms (46). Fourth, it is possible that other pathways independent of AR
may be activated in CRPC. For example, AKT activated by loss of PTEN can bypass AR
and further inactivate some pro-apoptotic proteins (i.e., BAD and procaspase-9) by
phosphorylation (196). Fifth, pre-existing castration-resistant PCa cells may play a vital role
for the development of CRPC, which bears SC properties. For example, as mentioned in
Chapter 1, it has been shown that CARNs represent a cell of origin for PCa and it has been
postulated that CARNs in prostate tumors may feature CSC characteristics (2, 21, 38).
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Finally, there have been other proposed mechanisms, some of which include enhanced
inflammatory reactions (197, 198), and increased expression levels of neuropeptides (199).

4.1.3. Current studies of castration-resistant prostate cancer stem cells (CaRP- CSCs)
Of all the proposed mechanisms discussed above, the concept of CaRP-CSCs is
perhaps the most interesting although the identification of such cells has not been reported.
The abundance of N-cadherin+ cells and the expression levels of N-cadherin are significantly
higher in CRPC xenografts, compared to the levels in their isogenic ADPC xenografts (200).
Also, N-cadherin is highly expressed in metastatic patient samples. In addition, ectopic
expression of N-cadherin in ADPC cells (i.e., LNCaP, MDA-PCa-2b, and LAPC4) greatly
increases their castration resistance and invasiveness as well as metastatic potentials, and
specific monoclonal antibodies against N-cadherin can significantly delay CRPC
progression (200). This data suggests that N-cadherin may play an intimate role in
regulating CRPC development, and that N-cadherin+ CRPC cells may be enriched in CaRPCSCs, although further study is needed to test this latter suggestion. A recent report has
shown that the expression levels of the cell surface maker CD166 are highly upregulated in
both WT mouse prostatic cells after castration and human CRPC samples. Moreover,
LSChiCD166hi cells from a PTEN null PCa model have significantly increased tumor sphereforming abilities, compared to the other isogenic cells (201), indicating that CD166hi cells
may be enriched in PCSCs that are resistant to castration. In addition, our recent study has
shown that PSA-/lo PCa cells are more clonal, clonogenic and tumorigenic than the isogenic
PSA+ PCa cells (98) in androgen-deprived conditions, suggesting that PSA-/lo PCa cells
likely represent a subpopulation of stem cell-like cells that are able to initiate CRPC.
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To further enrich CaRP-CSCs in the PSA-/lo PCa cells, we performed a cDNA
microarray analysis comparing PSA-/lo and isogenic PSA+ LAPC9 PCa cells, and observed
that dozens of developmental and (cancer) stem cell markers are highly expressed in PSA-/lo
cells, including Nanog, Bcl-2, KIT, ALDH1A1, CD44, integrin α2, SOX12, etc (98). Among
these genes, we were particularly interested in ALDH1A1, CD44 and integrin α2, each of
which has been reported to be preferentially expressed in PCSCs (85, 87, 91, 93). Therefore,
we used the combinatorial markers to purify ALDH+CD44+α2β1+ PCa cells from different
models, and tested their castration-resistant properties in vitro and in vivo. We hypothesized
that ALDH+CD44+α2β1+ PCa cells represent a population of CaRP-CSCs.
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4.2. Materials and Methods
Basic procedures have been described in earlier reports (96, 98) and Chapter 3.

Establishment of androgen dependent (AD) and androgen independent (AI) tumor
lines
As shown in Figure 4-2, the AD xenograft tumors (i.e., LAPC9 AD) were generated
by injection of the original xenograft tumor cells or cultured cells into intact
immunodeficient mice (i.e., NOD/SCID) supplemented with testosterone pellets (TP), in
which the majority of AD PCa cells are PSA positive (>90% PSA+). Simultaneously, the AI
xenograft tumors (i.e., LAPC9 AI) were reconstituted by injection of the same original
tumor cells into castrated immunodeficient mice supplemented with bicalutamide. This
process was repeated at each generation.

FACS analysis/sorting and purification of ALDH+CD44+α2β1+ cells
Single PCa cells were obtained from xenograft tumors (AD and AI) and primary
HPCa samples. These cells were then treated with FcR blocking agent for 10 min at 4°C,
and stained with a primary mouse anti-human antibody against α2β1 (MAB1998Z, Millipore)
for 30 min at 4°C followed by an APC conjugated goat anti-mouse IgG secondary antibody
(550826, BD Bioscience) for 30 min at 4°C. Cells were then washed with PBS three times
and incubated with a PE conjugated mouse anti-human CD44 antibody (555479, BD
Pharmingen) and a biotinylated mouse H-2K[d] antibody for 30 min at 4°C. Cells were then
washed with PBS and labeled with Alexa Fluor 405 conjugated streptavidin (Invitrogen, S32351) for 10 min at 4°C. Subsequently, cells were washed three times and treated with the
ALDEFLUOR assay kit (01700, Stem Cell Technology, Vancouver, Canada) according to
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the manufacturers’ protocol (68, 81, 98). In brief, PCa cells were suspended in
ALDEFLUOR assay buffer containing ALDEFLUOR substrate with or without the ALDH
specific inhibitor DEAB for 40 min at 37°C. As a result, the substrate is converted to a green
fluorescent product by ALDH, and detected by FACS in the FITC channel. The stained PCa
cells were then washed with PBS twice and re-suspended in cold ALDEFLUOR assay
buffer. Finally, PCa cells were stained with propidium iodide (PI) to determine viability
before FACS analysis.

Sphere-Formation Assays
Purified ALDH+CD44+α2β1+ PCa cells were plated in 6-well ULA plates containing
CDSS medium at the density of 5,000–10,000 cells/well depending on cell type. Spheres
were scored after ~2-4 weeks. For serial sphere-formation assays, the first-generation
spheres were harvested with 0.025% trypsin/EDTA, triturated with a 27-G needle, filtered
through a 40-µm strainer, and replated as above. This process was repeated for up to 3
generations.

Western blot
Whole cell lysates were prepared in complete RIPA buffer containing a protease
inhibitor mixture. Protein concentrations were determined by MicroBCA kit (Pierce).
Various amounts of proteins were loaded on a 15% SDS-PAGE gel. A standard western blot
was performed using ECL Plus (PerkinElmer). Primary antibodies included: mouse mAb to
AR (sc7305, Santa Cruz), mouse mAb to PSA (sc7316, Santa Cruz) and rabbit pAb β-actin
(4967, Cell Signaling).
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Figure 4-2. Experimental scheme for establishing AD and AI xenograft tumor lines.
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4.3. Preliminary Results

The abundance of ALDH+CD44+α2β1+ PCa cells is significantly higher in androgen
independent tumor lines
We have successfully established different pairs of AD and AI PCa xenograft tumor
lines, including: LAPC9 AD and AI, LAPC4 AD and AI, LNCaP AD and AI, HPCa101 AD
and AI, HPCa70 AD and AI, etc. To determine the expression levels of the triple markers
(ALDH+CD44+α2β1+ or TM+), we performed a FACS analysis on LAPC9 AD and AI tumor
cells. We have reproducibly found that LAPC9 AI tumors contain significantly more TM+
PCa cells (~18.5%) than the corresponding AD tumors (~2.2%), as shown in Figure 4-3.
Similarly, ~0.02% LNCaP AI tumor cells are triple-marker positive, whereas only ~0.002%
LNCaP AD tumor cells are positive for these markers. In addition, a similar pattern can be
detected in HPCa101 tumor cells, i.e., ~0.003% AD tumor cells and ~0.2% AI tumor cells
are triple-marker positive. Furthermore, we have consistently found that subsets of TM+ PCa
cells in two other well-known AI PCa lines, Du145 and PC3, in which TM+ cells are ~8.8%
and ~11.6%, respectively. Taken together, this data suggests that a subpopulation of PCa
cells, manifested as ALDH+CD44+α2β1+ PCa cells, become enriched after androgen
deprivation.

ALDH+CD44+α2β1+ LAPC9 PCa cells possess long-term tumor-initiating capacity in
castrated male mice and have sphere-forming abilities in androgen-deprived conditions
To characterize whether ALDH+CD44+α2β1+ PCa cells are CaRP-CSCs, we purified
ALDH+CD44+α2β1+ and isogenic ALDH-CD44-α2β1- (TM-) PCa cells from LAPC9 AI
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tumors, and tested their tumor-initiating capacities in the fully castrated mice (castration +
bicalutamide) using limiting-dilution assay (98). As shown in Figure 4-4, at the 1st
generation, TM+ LAPC9 AI cells were significantly more tumorigenic than TM- LAPC9 AI
cells. For example, TM+ LAPC9 AI cells, in a cell dose dependent manner, could initiate
tumor development with as few as 10 cells, whereas TM- LAPC9 AI cells could only
regenerate tumors at the injection of 10,000 cells. Furthermore, the TM+ LAPC9 AI cells
showed a TIF of ~1/448, while TM- LAPC9 AI cells showed a TIF of ~1/21,298, suggesting
that TM+ have ~48-fold enrichment of tumor-initiating ability compared to TM- cells in fully
castrated hosts. Interestingly, a similar pattern could be observed in later generations of
LAPC9 AI tumors, and the abundance of TM+ cells was consistent during serial
transplantations, suggesting that TM+ cells can self-renew in vivo. To further examine if
TM+ cells are the most tumorigenic among all subpopulations, we sorted out TM+ and TM+depleted LAPC9 AI cells and again determined their tumor-initiating capacities in castrated
mice. Remarkably, the TM+ LAPC9 AI cells were also more tumorigenic than the TM+depleted cells (Figure 4-5).
To test the clonogenicity of TM+ cells, we used sphere formation assays. When
purifying TM+ and TM- LAPC9 AI cells, we plated them in 6-well ultra-low attachment
plates. In ~2 weeks, we observed that TM+ cells could form more and larger spheres than
TM- cells. Furthermore, a similar pattern could be detected in serially formed spheres
(Figure 4-6).

Primary prostate tumors contain ALDH+CD44+α2β1+ PCa cells
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To extend our work to primary PCa cells, we obtained ~10 patient samples, from
GS6 to GS9 (2 GS6, 5 GS7 and 3 GS9) (Table 4-1). We consistently observed that each
sample contains a subset of cells that are triple-marker positive. However, we have not yet
found any correlation between the abundance of primary TM+ PCa cells and tumor grade.
Our functional characterizations are ongoing.
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Figure 4-3. Abundance of ALDH+CD44+α2β1+ cells in LAPC9 AD and AI tumors.
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Figure 4-4. ALDH+CD44+α2β1+ LAPC9 AI cells were significantly more tumorigenic
than the isogenic ALDH-CD44-α2β1- cells. Triple marker-positive and -negative LAPC9
cells were purified from AI tumors and reimplanted at the indicated cell doses in fully
castrated NOD/SCID mice. Adapted from (98) with permission from Elsevier.
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Figure 4-5. TM+ LAPC9 AI cells were significantly more tumorigenic than the isogenic
TM+- depleted cells.
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Figure 4-6. Characterization of clonogenicity of both TM+ and TM- LAPC9 AI cells
using sphere formation assays.
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Table 4-1. Triple marker analysis in purified primary prostate cancer cells.
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4.4. Future Studies
Our preliminary data has shown the presence of ALDH+CD44+α2β1+ (TM+) PCa
cells in long-term cultured cell lines, androgen-independent xenograft tumors, and untreated
primary HPCa specimens. One of the most important facets of these TM+ PCa cells is our
finding that they are more clonogenic and tumorigenic than the other isogenic
subpopulations of PCa cells in androgen deficient conditions. For our future studies, we plan
to further phenotypically identify and functionally characterize CaRP-CSCs.
First, we will examine the expression levels of triple markers in primary CRPC
patient samples. To achieve this, we will obtain paraffin-embedded tissue microarrays
containing tissues of normal prostate (n=44), androgen-dependent PCa (n=98), and
castration resistant PCa (n=230) from Dr. Arul Chinnaiyan (University of Michigan) (202).
We will use these samples to perform multi-color immunofluorescent staining in tissue
microarrays using primary antibodies against ALDH, CD44 and α2β1, followed by different
fluorophore-conjugated secondary antibodies. Images will be captured by a Zeiss confocal
microscope (81).
Second, we will further characterize stem cell-related properties of TM+ PCa cells in
CRPC xenograft models. Because fresh primary CRPC patient samples are very limited, we
will use early-passage CRPC xenograft models to mimic clinical PCa progression and
complete the assays listed below.
1) FACS analysis of the abundance of TM+ PCa cells: Currently, our preliminary
data has focused on the LAPC9 model, and we will now extend our functional studies to
other CRPC xenografts. We will perform a FACS analysis on single PCa cells from pairs of
AD and AI tumors as well as CRPC cell lines to determine the relative abundance of TM+
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PCa cells among all these models. The samples will additionally be screened by western blot
to determine the expression levels of the various markers. We expect that AI PCa
(CRPC/AIPC) will contain significantly more TM+ PCa cells than AD PCa (ADPC) (as
shown in LAPC9). After screening our samples, we believe that we will be able to identify
other 1-2 AI PCa models (other than LAPC9 AI) for our in vitro and in vivo
characterizations.
2) In vitro characterization of SC properties: We will purify TM+ and TM- cells from
the above selected CRPC xenografts, and test their self-renewal capacity using a serial
sphere-formation assays in androgen deficient conditions (CDSS medium plus bicalutamide).
Furthermore, both TM+ and TM- AI cells will be tested for their clonal and proliferative
capacity using clonal assays and BrdU incorporation assays (85, 96, 98) in CDSS medium
plus bicalutamide. In addition, we will treat TM+ and TM- AI cells with commonly used
therapeutic drugs for PCa (e.g., etoposide and paclitaxel) to examine their drug-tolerant
potentials.
3) In vivo characterization of SC properties: Freshly purified TM+ and TM- cells of
the selected CRPC xenografts will be tested for their tumor-initiating capacities via LDA
and serial tumor transplantation assays in fully castrated mice. Tumor incidence, latency,
tumor volume, and endpoint tumor weight will be monitored twice a week starting from the
second week. In addition, we will perform LRC experiments using BrdU pulse-chase assays
(98) to determine the quiescence of TM+ and TM- PCa AI cells. Based on our preliminary
studies, we predict that TM+ PCa AI cells are more quiescent, clonal, clonogenic,
tumorigenic and drug-tolerant than isogenic TM- PCa AI cells.
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Third, we will study the underlying molecular mechanisms that regulate
ALDH+CD44+α2β1+ HPCa cells in CRPC. Global transcriptional profiling using microarray
analysis will be performed on TM+ and TM- CRPC cells. Gene Ontology (GO) analysis will
be employed to assign differentially expressed genes into distinct functional categories,
including developmental and (cancer) stem cell molecules/markers, cell cycle,
transcription/nuclear factors, cell survival/death, etc. We will be particularly interested in
(cancer) stem cell-related genes based on our preliminary data that TM+ PCa AI cells have
SC properties. We will select several genes that are significantly upregulated in TM+ cells
compared to TM- cells, which have been identified in the literature as having potential roles
in PCa progression. Next, qPCR will be used to validate microarray data of the selected SCrelated molecules. Subsequently, to obtain a better understanding of how these molecules
potentially regulate CRPC development, a lentiviral-mediated gene knockdown of these
molecules will be performed in TM+ cells. Serial sphere-formation and LDA assays will be
employed to characterize their CSC properties in androgen deficient conditions. In a
reciprocal experiment to further confirm the gene knockdown results, a lentiviral-mediated
gene overexpression of these molecules will be conducted in TM- cells, followed by
characterization of their CSC functions in vitro and in vivo in androgen deficient conditions.
We believe that these experiments will allow us to narrow our selection to 2-3 SC-related
molecules, which have the most significant phenotype after knockdown and/or
overexpression experiments. Finally, to uncover the involvement of our selected SC-related
molecules

in

CRPC

progression

at

a

global

molecular

level,

a

chromatin

immunoprecipitation sequencing (ChIP-Seq) analysis in both TM+ and TM- CRPC cells will
be performed on 3 histone marks, i.e., H3K4me1, H3K4me3, and H3K27me3. By
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combining the genome-wide protein-DNA binding profiles and IPA software (Ingenuity
Systems), we will be able to analyze a group of genes or signaling pathways that are
potentially regulated by our selected SC-related molecules. After we complete the proposed
studies, we should have a better understanding of how the selected SC-related molecules
regulate CRPC. Our lab is currently optimizing our ChIP-Seq protocols by using FACS
sorted cells, which will facilitate this study in the future.
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Chapter 5

Conclusion and Perspective
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Ever since Dr. John Dick and his colleagues reported the first CSC population in
AML, the concept of CSCs has flourished and been widely tested in different tumor systems
(4, 6-8, 51). It has been demonstrated that PCa contains distinct subsets of PCSCs that may
play a role in PCa initiation and progression. Understanding and molecularly dissecting the
PCSCs may help us to elucidate the etiology of PCa and uncover the molecular mechanisms
responsible for its androgen-independent progression.
Although we have made significant progress in the study of PCSCs, there are several
critical issues to be resolved, some of which have been studied and presented in this
dissertation. Firstly, it is not fully known whether PCSCs are therapy-resistant. In Chapter 2,
we have shown that several cancer cell lines (i.e., Du145, DLD1 and UC14) chronically
treated by anti-cancer drugs generate drug-tolerant cancer cells (DTCs). Surprisingly, these
DTCs show greatly reduced tumor-initiating capacities and clonogenic abilities, which are
contrary to the general assumption that CSCs are drug-resistant and, vice versa, DTCs
possess CSC properties. In drug-tolerant Du145 cells, we have further demonstrated that the
reduced CSC activity is associated with the depletion of cancer stem/progenitor cells (i.e.,
CD44+ cells in our study) after chronic treatment of cells with chemotherapeutic drugs (e.g.,
etoposide and taxanes), which further substantiates the importance of CD44 in PCa. In
addition, we have provided evidence that the drug-tolerant phenotype is reversible,
indicating some epigenetic regulations may be involved. Secondly, it remains unanswered
whether primary patient PCa samples also contain PCSCs because the relevant tumor
experiments are lacking. It is well known that establishing HPCa development in
immunodeficient mice using single patient cells is extremely challenging. In Chapter 3, we
have employed three different stromal cells (rUGM, CAFs and Hs5) and two

138	
  
	
  

immunodeficient mouse strains (NOD/SCID and NSG) in many of the 114 patient samples,
to establish a reliable system that allows us to reproducibly reconstitute HPCa development
in immunodeficient mice using single patient tumor cells. Our results have shown that
coinjection of primary HPCa cells with immortalized Hs5 bone marrow derived stromal
cells in NSG mice can generate undifferentiated tumors, providing indirect evidence that it
is possible that undifferentiated PCa cells are responsible for tumor formation. Finally, most
advanced PCa patients will progress from ADPC to CRPC even after tumor regression by
ADT, and the exact mechanisms responsible are not completely understood. Herein, we
have shown preliminary evidence that the ALDH+CD44+α2β1+ (TM+) PCa cells possess
CSC properties in androgen deficient conditions, and they may represent a cell-of-origin for
CRPC.
Future studies will be needed to further characterize PCSCs in primary patient
samples with improved techniques and optimized protocols in suitable systems, and it will
also be meaningful to have a better understanding of the functional roles of PCSCs in PCa
progression, therapy resistance and metastasis. The success of these projects will
undoubtedly facilitate future drug development targeting PCSCs more efficiently and
effectively, and ultimately benefiting PCa patients.
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